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ABSTRACT 
Mycobacterial species are ubiquitous in nature and a worldwide concern for human and animal 
health. The major mycobacterial infections in animals are Johne’s disease (JD) and bovine 
tuberculosis (bTB). Controlling these infections is difficult due to the lack of highly sensitive and 
sensitive diagnostic test. Currently available diagnostic tests have to be carried out in laboratory 
settings with well experienced and trained examiners. My goal is to develop a sensitive on-site 
(in-field) device for diagnosis of Johne’s disease and bovine tuberculosis. The specific aims of 
this thesis were (1) to review currently-used or recently developed diagnostic tests for 
mycobacterial infections, (2) to optimize a milk-based enzyme linked immunosorbant assay 
(ELISA) for diagnosis of JD, (3) to evaluate a serum-based ELISA for detection of bTB in red 
deer and (4) to develop a bead-based microfluidic assay as a prototype of on-site diagnostic 
device for JD.  
Previous reports on currently-used or recently developed diagnostic tests for 
mycobacterial infections were reviewed to summarize challenges and opportunities in 
development of sensitive on-site diagnostic devices. Most of the current serological tests for 
mycobacterial infections utilize crude extract of the pathogen or single molecule causing low 
diagnostic specificity and specificity. Use of multiple antigens was shown to be effective in 
improving test accuracy.   
Ethanol extract of Mycobacterium avium subspecies paratuberculosis (MAP) was used to 
optimize a serum ELISA to test milk samples for JD. Using the optimized conditions, the 
average of ELISA values in the JD-positive milk samples was found to be significantly higher 
than that in the JD-negative milk samples.   
vi 
 
Using ethanol extract from Mycobacterium bovis (MB), an ELISA was developed to 
detect anti-MB antibodies in serum of farmed red deer. The tentative diagnostic sensitivity and 
specificity was estimated to be 90% and 93.3%, respectively.  
Magnetic beads coated with ethanol extract of MAP were used to develop a microfluidic 
immunoassay for diagnosis of JD. The antigen-coated magnetic beads were tested in the 
microfluidic system using bovine serum samples and a high level of antibody binding in JD-
positive serum was observed. 
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CHAPTER 1 
 
INTRODUCTION  
 
Opportunities for improved serodiagnosis of human tuberculosis, bovine tuberculosis and 
paratuberculosis.  
Mycobacterial species are causing serious concerns in livestock and wild animals 
worldwide. For example, Johne’s disease (JD) or paratuberculosis is caused by Mycobacterium 
avium subspecies paratuberculosis (MAP). It is chronic infectious enteritis of domestic and wild 
ruminants, causing reduction in milk production, malnutrition, weight loss and eventually death. 
The causative agent of bovine tuberculosis (bTB), Mycobacterium bovis (MB), infects not only 
cattle but also humans and various wild animals. During 2005 – 2008, 128 countries have 
reported the presence of MB infection and /or clinical disease in their cattle population. bTb 
eradication programs in USA and Great Britain have been spending more than $ 40 and £ 100 
million per annum, respectively. Since mycobacterial infections are chronic in nature and there is 
lack of treatment measures, the best strategy to control the infection is through early 
identification of the infected animals and removal from the herd. Better diagnostic measures are 
required for effective control programs. In the past, diagnostic tests are based on antigens which 
were cross reactive among the closely related mycobacterial species and thus, had poor 
specificity. Also, diagnostic tests based on direct observation of the bacilli have poor sensitivity 
since they require a large number bacilli in the specimen used for the test. Also, current 
diagnostic tests are not suitable to be used in resource limited setting where mycobacterial 
infections are endemic, due to requirement of proper laboratory settings. Diagnosis of 
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mycobacterial species based on species specific lipidic antigens has been validated in many 
recent studies. In the following chapter, we focused on summarizing the available diagnostic 
tests, discussion on recent development in the technology of diagnostics and provided a 
perspective on the future of lab-free diagnostic devices for mycobacterial infections.   
 
Optimization of serum EVELISA for milk testing of Johne’s disease. 
An important first step towards the control of JD is the identification of infected cattle. 
Another step would be to minimize the spread of MAP infections by applying regulations to 
prevent movement of animals from infected herds to JD-negative herds. These approaches of JD 
control require identification of MAP-infected animals with a diagnostic test. However, the 
currently available diagnostic tests have poor sensitivity. A consensus report recommended the 
use of enzyme linked immunosorbent assay (ELISA) for the control of JD in dairy herds to 
reduce the economic impact of the infection. Milk ELISA has been shown to have similar 
sensitivity as compared to the serum ELISA and has the potential to be used to identify cattle at 
high risk for MAP infection without costly visits for collection of serum and fecal samples used 
in traditional programs. Furthermore, herd-level estimates of MAP infection determined by 
routine, high-throughput analysis of available milk samples could be used to quantify and 
monitor the risk of individual cattle within the National Dairy Herd Information Association 
enrolled herds. Dairy owners have already invested in milk sample collection, so additional 
testing can benefit them in lower cost per test. Keeping in view the advantages of milk testing, 
we used antigens extracted by briefly vortexing the MAP bacilli in ethanol solution to develop a 
novel milk based ELISA. Using the optimized conditions for detection of antibodies in milk, 57 
milk samples (37 animals – JD-positive by the fecal PCR test; 20 animals – negative and from 
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JD-free herds) from Holstein dairy cattle were tested. The in-house milk based ELISA showed 
improved performance when compared with a commercially available ELISA test. 
 
Use of ethanol vortex enzyme linked immunosorbent assay for diagnosis of bovine 
tuberculosis in farmed red deer (Cervus elaphus): 
The infection of MB in wildlife species can cause problems of biodiversity and species 
conservation. Also, some of the wildlife species can act as reservoir of the MB infection and spill 
it over to the domestic livestock population. Since postmortem examination of each suspected 
animal is not practical, serological tests for the detection of bTB have been recommended. 
Previous studies have developed diagnostic tests based on crude extracts and specific molecules 
in a single or multiple antigen formats, but still these tests have poor specificity. Co-infection 
with MAP has been found as a confounding factor for the poor performance of these tests. We 
used ethanol extract of MB and developed a serum based ELISA test for the detection of anti-
MB antibodies. To detect the presence of anti-MB antibodies, a total of 50 red deer samples from 
4 different studies in New Zealand were tested using heat killed MAP (sheep strain) as absorbent 
of cross reactive antibodies. The tentative diagnostic sensitivity and specificity was estimated to 
be 90% and 93.3%, respectively. The results from this study suggest that ethanol extract based 
ELISA could be used to diagnose bTB in red deer with minimum false positive results.  
 
Bead-based microfluidic immunoassay for diagnosis of Johne’s disease: 
Microfluidics or Lab-on-a-chip technology, has been used in various analytical processes, 
including electrophoresis, single-cell analysis, biochemical assays, and immune assays. The 
technology offers opportunities for the development of point-of-care diagnostic devices for 
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various infectious diseases. In the recent years, rapid diagnostic tests have been developed based 
on multiple antigens, which are highly purified. However, these molecules are complicated and 
costly to isolate. Ethanol extract coated magnetic beads were used in flow cytometric and 
microfluidic systems to develop an onsite diagnostic device for JD. A total of 155 well classified 
serum samples from JD-positive and JD-negative cattle were tested in the bead-based flow 
cytometric assay. The specificity for this assay was estimated to be 98%. The sensitivity was 
estimated to be 45.7%, 48.6% and 85.7% for low, medium and high shedders, respectively. 
Antigen coated magnetic beads were also tested in the microfluidic system using 5 serum 
samples and a high level of correlation (linear regression, r2 = 0.994) was observed with the 
bead-based flow cytometric assay. The results from the study suggest that this technology could 
form a basis for onsite diagnosis of JD.  
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CHAPTER 2 
OPPORTUNITIES FOR IMPROVED SERODIAGNOSIS OF HUMAN 
TUBERCULOSIS, BOVINE TUBERCULOSIS AND 
PARATUBERCULOSIS 
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A version of this chapter hasn’t been published anywhere but is submitted to the special 
issue on Mycobacterial diseases to be published by the Journal of Veterinary Medicine 
International.  
The manuscript based on this chapter has been reviewed by 3 reviewers and it was 
recommended for minor revisions. The reviewers have asked us to divide the various sections 
into sub-sections and put more emphasis on recent developments in the field of lab-on-a-chip 
technology for infectious diseases.  
 
Opportunities for improved serodiagnosis of human tuberculosis, bovine tuberculosis and 
paratuberculosis  
 
Ashutosh Wadhwa, Graham J. Hickling and Shigetoshi Eda 
 
2.1 Abstract:   Current serodiagnostic methods for tuberculosis (TB), bovine tuberculosis (bTB) 
and Johne’s disease (JD) exhibit low sensitivity and/or specificity, due in part to potential 
exposure of test subjects to other environmental mycobacteria. A review of recent attempts to 
improve diagnostic test performance indicates that the use of multiple antigens can improve the 
efficacy of serodiagnosis of these mycobacterial diseases. Most recent studies that have aimed to 
develop improved serodiagnostic tests have focused on protein antigens. Since mycobacteria are 
known to produce a variety of species-specific lipidic molecules, efforts to identify lipidic 
diagnostic antigens may be a useful contribution to the development of more specific tests for 
TB, bTB and JD. Accurate laboratory-free diagnostic devices would be particularly valuable in 
understanding the epidemiology of the mycobacterial infections and in facilitating their control. 
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The emergence of new technologies such as microfluidics and ‘Lab-on-Chip’ is creating 
promising opportunities for development of laboratory-free diagnostic devices for these 
mycobacterial infections.  
 
Key words: Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium avium 
subspecies paratuberculosis, onsite diagnosis, immunoassay.  
 
 
2.2 Introduction 
Mycobacterial infections are a leading cause of health concerns in humans and animals 
worldwide. Mycobacterium tuberculosis (MTB), Mycobacterium bovis (MB) and 
Mycobacterium avium subspecies paratuberculosis (MAP) are the causative agents of human 
tuberculosis (TB), bovine tuberculosis (bTB) and Johne’s diseases (JD), respectively. In 2009,  
more than 9 million cases of TB were reported, causing 1.8 million deaths [1].  Multidrug 
resistant TB strains and co-infections of TB and HIV are emerging problems globally [2-4].  
Despite much progress in eradicating bTB in developed countries, this disease is nevertheless 
responsible for US$ 3 billion economic losses globally [5], and remains prevalent in some 
wildlife species [6-7]. MAP is present in 68 % of US dairies [8], with JD responsible for an 
annual $220 million economic loss to the US dairy industry  [9].  
 Control measures for these mycobacterial diseases revolve around understanding their 
epidemiology and improving treatment/vaccination protocols, however a major bottleneck has 
been the lack of efficient diagnostic methods [2, 10-12].  Consequently, there would be much 
benefit to the development of  rapid and accurate diagnosis of TB at point-of-care [3], however, 
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efficient laboratory-free (lab-free) diagnostic devices for TB are not yet available [13-14]. 
Similarly, the most common current diagnostic test for bTB, the tuberculin skin test (TST), is not 
practical for controlling of bTB in wild animals, so a lab-free diagnostic device would also be 
helpful in this context.  Diagnosis of JD is currently conducted annually or bi-annually in 
diagnostic laboratories.  If a lab-free diagnostic device becomes available, it would reduce the 
long time interval and cost of diagnosis. Thus, there would be great value in lab-free diagnostic 
technologies for TB, bTB and JD [13, 15].  
Here we briefly review currently-available and recently-developed diagnostic methods 
for these three mycobacterial diseases, and highlight the potential benefits of lab-free diagnosis. 
Since serodiagnosis has been the most favored format for development of lab-free diagnostic 
method, we focus this review on methods of serodiagnosis over other diagnostic methods such as 
bacterial culture and nucleic acid amplification that are necessarily laboratory-based. 
 
2.3 Human tuberculosis 
Human tuberculosis (TB) is caused primarily by MTB, and occasionally by MB and M. 
africanum (in this paper we focus on MTB).  TB is a leading cause of morbidity and mortality 
throughout the world [16]. One-third of the world’s population is infected by MTB although only 
5-10 % of infected individuals develop an active, life-threatening form of the disease. In 2009, 
9.4 million cases of TB were reported with 1.8 million deaths worldwide [1-2]. MTB is 
transmitted through aerosols from infected individuals and attacks the pulmonary system. It also 
affects brain, spinal cord, circulatory, gastrointestinal, uro-genital systems; skin, bones and joints. 
Active TB is a progressive disease that progressively impedes vital organ function, leading to 
severe morbidity and death [17].   
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 Depending on the pathogenesis, infectivity, immune response and effectiveness of 
treatment, TB can be divided into 3 major forms. The first is the active form of TB (TBA), which 
results in rapid development of clinical signs in patients following contact with MTB. TBA 
develops in only 5% of infected with MTB; the remainder develops a strong acquired immune 
response showing no clinical signs, termed latent TB (TBL) [18].  Infection will reactivate in a 
small proportion (1-2%) of individuals with TBL, who then develop clinical disease. The TBL 
group, which  constitutes one-third of the world’s population, is most important in terms of 
controlling MTB infections [19]. The third form is multidrug resistant TB (MDRTB), which 
constitutes approximately 5% of the global TB cases [20]. MDRTB is caused by organisms 
resistant to, at least, isoniazid and rifampin [21]. The overall prevalence of MDRTB in 
developed nations is much lower than that in developing nations, but can be high in immigrant 
populations and among prisoners and immuno-compromised individuals [22, 23]. In the last two 
decades, the emergence of HIV infection led to the recognition that TB/HIV co-infection 
promotes both the reactivation of TBA from TBL and also the rapid progression of primary TB 
following recent exposure to MTB [22].  
 Controlling TB depends on the following factors - case detection, treatment of 
individuals with TBA, improving anti-TB therapy to prevent resistance, identification of TBL, 
and better vaccination strategies for susceptible individuals [16]. All these factors regarding 
control revolve around the need for a better understanding of the epidemiology of the TB 
infection [23] and the development of evidence-based approaches for its diagnosis [24]. Efficient 
diagnosis of TB is particularly important in third world nations that lack proper diagnostic 
resources at primary health care centers. In these nations, TBL and MDRTB often remain 
undiagnosed, which facilitates further transmission.  
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 Presently, there are a number of alternative diagnostic approaches towards diagnosis of 
TB, and of TB co-infection with other emerging infectious diseases.  Radiographic imaging is 
still widely used to diagnose TB, however previous studies have shown that there are no 
definitive diagnostic patterns, so that the method can be used only for screening of TB cases; 
further bacteriological examinations are required for confirmation [19, 25]. Smear microscopy of 
stained sputum or other clinical material is the most common test for TBA. This relatively 
inexpensive method can be carried out rapidly in low resource settings, however it lacks 
sensitivity and requires a large number of bacilli (5,000-10,000 organisms/sample) [19, 26] in the 
clinical specimen, which is often not the case in children, advanced stage TBA patients and 
individuals co-infected with HIV. Fluorescent microcopy is more sensitive, but its application is 
limited by cost and by issues relating to the use of mercury vapor lamps in conventional 
fluorescent microscopes [27].  Nucleic acid amplification (NAA) assays have been found useful 
for diagnosis of TBA and MDRTB infections, as they have high specificity and sensitivity, and 
can provide results within few hours. Unfortunately, these assays are costly, require a laboratory 
with trained staff, and suffer from poor specificity under field conditions [19, 28-29].  
 Bacterial culture is considered the gold standard for TBA diagnosis, having almost 98% 
specificity, and is also useful in diagnosis of MDRTB. However, the bacterial culture method 
suffers from low sensitivity (26-42%), a long growth period (6-8 weeks), the requirement of 
trained personnel, and the high cost of the culture examination. The need for technical expertise 
can be particularly problematic in developing nations. Attempts are being made to improve this 
assay by incorporating a number of growth indicators but culture still requires optimization at 
various levels - detections time, susceptibility testing against anti-TB drugs and need for disposal 
of radioactive waste [19, 30-31]. Parsons et al. (2011) has suggested new technologies, including 
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urine antigen detection, assays based on volatile markers, bead based and flow cytometric based 
assays [3], but these assays require optimization and establishment of clinical utility.  
The tuberculin skin test (TST) – based on detection of delayed-type hypersensitivity after 
an intradermal injection of purified protein derivative (PPD) extracted from heat killed MTB – 
has been in use for almost a century. The primary roles of TST are to identify TBL individuals 
and to monitor recent infection in high risk groups. Some limitations of TST include a high 
frequency of false reactions, the need for a follow-up visit after 2-3 days of PPD inoculation, 
misleading results due to confounding factors (e.g. age, HIV infection, and infection with other 
mycobacterial species or cancer) and positive reactions in TBA patients [19, 27, 32]. Based on 
the identification of MTB-specific antigens using molecular techniques, detection of cell 
mediated immune (CMI) response against MTB infection has improved the diagnosis of TB. 
These assays measure the production of cytokines (mainly interferon-gamma [IFN-γ]) produced 
by T cells of MTB-infected individuals. Initial IFN-γ assays were based on PPD antigen but later 
the antigen was replaced by MTB specific antigens, such as early-secreted antigenic target 
(ESAT-6) and culture filtrate protein (CFP-10) [33]. IFN-γ assays do provide an improved 
diagnosis of TBL; however, since they detect the presence of the host’s CMI response towards 
MTB antigens, fresh blood samples are required for the test. Inability to differentiate between 
TBA and TBL, poor reproducibility, and reduced efficacy in children are additional problems of 
the CMI-based diagnostic tests [34]. In developing countries, TST is still preferred over IFN-
γ assay due to its lower cost; but suffers from low efficacy in children, poor reproducibility, and 
reduced diagnostic accuracy for TBL [34-36].  
 In circumstances where medical resources (facilities and health care providers) are 
limited, serodiagnostic methods for detection of anti-MTB antibodies have some advantages (i.e., 
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simplicity, low cost, and requirement of minimum medical resources) over aforementioned 
diagnostic methods [37].   Several target molecules (antigens) have been used to detect the 
humoral responses (anti-MTB antibodies) in TB patients. Early assays used PPD or other crude 
molecules as antigens for capturing anti-MTB antibodies; however, these showed poor 
specificity as dominant antibody responses are against cross-reactive antigens (i.e., antigens 
commonly found in MTB and also in other mycobacteria) [38]. As molecular techniques have 
improved, many antigens have been evaluated in serological tests, especially in the format of the 
enzyme linked immunosorbant assay (ELISA). Some major antigens used in such tests are 
discussed below.   
 Antigen 5, also known as 38 kDa antigen, is the best studied and most available antigen 
for MTB diagnosis due to its expression in the E. coli system.  Many attempts to develop an 
improved serological assay for TB have used this antigen [39-40]. Early studies reported 89% 
sensitivity and 100% specificity in TBA patients [41]. Later studies showed even higher 
sensitivity, proving a correlation between antibody level and bacterial load [42-45].  As 
summarized in a review article [46], detection of antibodies against Antigen85 complex in 
ELISA formats achieves 50% sensitivity; however, this complex is highly cross-reactive and 
may causes false positive results in individuals infected with atypical mycobacteria. A cell wall 
component, called a cord factor (trehalose-6,6'-dimycolate), used as antigen in ELISA format 
achieved 84% sensitivity with 100% specificity [47]. However in a following study, it was 
shown that anti-cord factor antibodies decline after anti-tuberculous chemotherapy, which makes 
it difficult to determine the status of the infection [48]. Studies of the serodiagnostic potential of 
ESAT-6 [49-50] and CFP-10 [49-52] have also been conducted. One showed low sensitivity 
(67%) and specificity (51%) for ESAT-6 [49]. Low sensitivity (48-63%) also has been reported 
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for CFP-10 [49, 53].  In high incidence areas, neither ESAT-6 nor CFP-10 antigens are useful in 
differentiating between TBA and TBL [49]. Another antigen, Kp 90, has been used in ELISA 
format to detect IgA antibodies against the protein; the results, when compared with NAA and 
other serological assays,  indicated that anti Kp 90 antibodies were detected in 78% of serum 
samples and 69% of samples from synovial, cerebrospinal and abscess body fluids. [54].  
 Antigen 60 (A60) is the main thermostable component of PPD [55-56]. Many studies 
have used this antigen and found almost 100% specificity [57], with sensitivity ranging from 68-
91% [58-59]. Unfortunately, this molecule has also been found in Norcardia and 
Corynebacterium species [60]. A 30 kDa antigen (isolated from a culture filtrate of MTB, 
Antigen 85B) was used in dot immunoassay and the result compared with that of standard plate 
ELISA. The specificities of the dot immunoassay and ELISA were 92% and 97%, respectively, 
and the sensitivities in the assays were 69% and 78%, respectively [61]. Further studies showed 
that this antigen not only diagnosed TBA but also detected non-the protective immune response 
of a healthy household contact group [62].  
 Malate synthase (MS), a 81 kDa protein (present in MTB culture filtrates, cell wall, and 
cytoplasmic subcellular fractions) is an enzyme of the glyoxylate pathway used by MTB during 
intracellular replication in macrophages [63]. Studies with an MS-based assay have shown a 
sensitivity of 73% and specificity of 98% in smear positive patients, suggesting that MS is a 
potential candidate for TB diagnosis [53, 64]. The cell wall of MTB also contains 
lipoarbinomannan (LAM), however its use as antigen in diagnostic tests is limited due to 
immune complex formation [3]. LAM antigen is found in urine of TBA patients and tests based 
on detecting the LAM in urine samples have been developed [65-67].  
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 Steingart et al. (2007) conducted an intensive meta-analysis of 67 studies published 1990-
2006 on commercial serological tests for TBA (e.g. Detect-TB, and a-TB ELISA, ICT TB test) 
[37]. Antigens used in the commercial tests include Antigen 60, 38-Kda protein, LAM, and Kp-
90. The meta-analysis revealed that estimated diagnostic sensitivities (0-100%) and specificities 
(31-100%) in the studies were inconsistent and imprecise, which is consistent with a WHO 
report in 2008 [68].  
 In patients co-infected with HIV and MTB, the level of antibody production to TB 
antigens differs from that of HIV-negative TB patients. For example, an ELISA based on 
MS/MPT51 antigens showed positive reactions in approximately 80% of HIV positive, TB 
positive patients and in 42% of HIV-negative, TB-positive patients. [69].  Wanchu et al. (2005) 
suggested that better diagnosis of TB will require a focus on development of multi-antigen based 
tests and identification of novel MTB proteins that increase in HIV patients [70].   
 The studies described above indicate that an improved diagnostic test is needed that is 
better able to differentiate the various forms of mycobacterial infection and to diagnose TB in the 
presence of HIV infection. Furthermore, since most deaths due to TB occur in developing 
countries that lack proper laboratory facilities and specialist training, it is important to develop a 
simple, rapid and cost-effective test.  The Xpert MTB/RIF assay has been recently used as point-
of-care diagnosis for MDRTB and drug sensitive TB [71-72]. Although simple to perform and 
highly sensitive, this assay is costly [73]. McNerney and Daley (2011) have summarized the 
importance of point-of-care diagnosis  [74] and suggest three important areas in which progress 
should be made to achieve better point-of-care for TB. The first is through identification of 
biological, metabolic and pathogen derived markers that will assist in understanding the disease. 
The second is the development of effective technologies like immunochromatography and 
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nanotechnology. The third is to better understand the economical and logistic constraints on the 
implementation of new tests [74]. In summary, there is an urgent need to develop a lab-free 
diagnostic device for TB that will decrease disease transmission rate, reduce death rates and 
permit faster initiation of treatment.  
 
2.4 Bovine tuberculosis 
Bovine tuberculosis (bTB), caused by Mycobacterium bovis (MB), is an infectious, chronic but 
progressive disease characterized by the formation of granulomatous lesions with varying 
degrees of necrosis, calcification and encapsulation [11]. MB is known to infect and cause 
tuberculosis in a wide range of wild animals, livestock animals, and humans. Although bovine 
bTB has been mostly eradicated in the livestock industry of developed countries, the disease in 
wildlife still poses a risk to livestock, tourism economy, and wildlife conservation [11]. Infected 
wildlife species include white-tailed deer (Odocoileus virginianus) in several states of the USA, 
Eurasian badgers (Meles meles) in Great Britain and the Republic of Ireland, and brushtail 
possums (Trichosurus vulpecula) in New Zealand [6]. Global economic losses from bTB total 
US$ 3 billion annually. In the USA, US$ 40 million and in Great Britain £100 million were spent 
on bTB management in the year 2008-2009 alone [5]. In developing countries, bTB still causes 
serious concerns not only for wildlife, but also for public health, food safety, and the economy of 
livestock industries.  
 Despite progress towards national eradication of bTB from livestock [5], a few U.S. 
states including Michigan and Minnesota continue to struggle with bTB in their wildlife [7, 75]. 
While many mammal species can become infected with MB, the white-tailed deer is one of the 
very few wildlife species that can act as a maintenance host for this organism [76]. In states with 
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infected wild deer, bTB is also found in cattle operations, with transmission from the wild deer 
being suspected.  Mandatory testing of cattle has cost $3.25 million per year in Minnesota [75]. 
bTB in wild, white-tailed deer in northeastern Michigan was first recognized in 1994 [77]. The 
Michigan Department of Natural Resources tested deer samples from 1999 until March 2009 and 
has found 632 positive samples of the 178,502 samples tested [78].  Current testing procedures 
for wild deer rely almost exclusively on inspection for gross lesions during postmortem of 
hunter-collected carcasses, which is thought to achieve only about 50% sensitivity.  
 In addition to the risk of infection from resident wildlife, the United States imports an 
average of 1.4 million beef calves annually from Mexico [79]. In spite of all efforts, a few of 
these animals are infected with bTB and thus are a possible source of infection to the cattle in the 
US. These infected Mexican cattle can be difficult to detect by screening at the border, because 
of lack of reactivity (i.e. false negative reactions) [79]. It has been suggested that regionalization 
would facilitate trade of animals and assist in bTB control by acting as biosecurity barrier against 
the spread of infection and by managing surveillance programs [80]. There are currently no 
effective vaccines or medications for bTB in animals, and therefore the most effective method of 
disease control is to test and cull infected animals.   Given the current lack of accurate live-
animal diagnostic tests for bTB, this test-and-slaughter approach can result in a large number of 
healthy animals being depopulated [81].   
 More accurate diagnosis of bTB would provide an opportunity to reduce the unnecessary 
sacrifice of healthy animals and would also help to more effectively control bTB. At present, 
postmortem diagnosis based on examination of gross lesions, followed by histopathology and 
culture, is widely used for surveillance of bTB in wild animals, but this method is time-
consuming and cannot diagnose an early infection [82]. The ante mortem diagnostic method 
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currently prescribed by OIE is the intradermal tuberculin skin test (TST) [83]. The TST is by far 
the most effective test used in the eradication of bTB in the developing countries. The test is 
performed by injecting a small volume of bovine tuberculin in the skin of the animal and 
palpating a change in the thickness of the skin at the site of injection after 48-72 hours. The 
tuberculin used in most of the countries is derived from cultures of MB AN5, a field strain 
isolated in England circa 1948 [5, 82, 84]. The TST is, however, susceptible to causing false 
positive reactions due to exposure of some animals to environmental mycobacteria such as M. 
avium and MAP [82, 85-87]. TST can also cause false negative reactions due to 
immunosuppression, desensitization towards tuberculin, sub-potent use of tuberculin, and time 
since exposure to field strain [82]. Steps have been taken to improve the specificity by using 
specific antigens, such as ESAT-6 [88] and a cocktail of ESAT-6/CFP-10/ MPB83, however 
these studies still need to be validated at a larger scale [5].  
 Revisiting the animal after 2-3 days application of the TST to check their reaction is labor 
intensive and usually impractical for wildlife species. The alternative IFN-γ assay is an in vitro 
blood test based on measuring the CMI response of the animals infected with  MB [89]. The 
IFN-γ assay is performed mainly using PPD as antigen but recent studies have also used ESAT-6 
and CFP-10 [90-93]. IFN-γ assay has some advantages over the TST — early detection and no 
need of revisiting the animal. A problem with the IFN-γ assay is that it is a costly process and 
requires well trained personnel to carry out the test [84, 94].  Bacteriological culture of clinical 
samples (i.e., milk, blood, nasal swab and cattle tissues) is considered to be the gold standard for 
bTB diagnosis but is a long process that may take several weeks [82, 95]. Nucleic acid 
amplification methods (e.g. PCR) have been also used for bTB diagnosis but these methods are 
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costly, less sensitive than the bacteriological culture test, and require a trained technician to 
perform the test [82, 95-97].  
 Another type of immunological test is based on detection of humoral immune response 
(i.e., antibody production). The major advantages of the antibody-detection tests are that they are 
inexpensive and relatively easy to perform. However, sensitivity of the antibody-detection tests 
remains a concern. Several attempts have been made to develop ELISA tests for detection of 
antibody response against MB infections. PPD was used as an antigen to measure antibody 
response in animals with MB infection [98-99], but the cross reactivity of PPD with closely 
related mycobacterial species has always been a concern. Auer (1987) used sonicated preparation 
of MB as antigen and reported low specificity [100]. Further studies used a specific protein 
isolated from MB bacillus Calmette-Guerin (BCG) strain, MPB70, as an antigen for developing 
assays for the diagnosis of bTB. The use of MPB70 suggested a better specificity but had poor 
sensitivity [101-102]. Ag85 complex consists of the major secretion products of MB BCG strain 
and have 3 major components 85A (31 kDa), 85B (30 kDa) and 85C (31.5 kDa). The Ag85 
complex is strongly immunogenic and has been used for development of assays to diagnose TB 
and bTB. However, low sensitivity was reported from studies using Ag85 in ELISA format and 
attributed to false positive reactions caused by infections with environmental mycobacteria [46, 
102-103]. MPB83 has been used as antigen in many studies and is a very promising candidate 
for bTB serodiagnosis [104]. As discussed in the TB section, LAM, ESAT-6 and CFP-10 were 
also used as antigens to detect antibody response against MB [105-110]. Further, as molecular 
biology tools have improved, recombinant proteins have come to be used as antigens for 
diagnosis of bTB. Since recombinant proteins can be produced at large scale, they are cost-
effective and provide consistency in their quality as diagnostic antigen [111-113]. One of the 
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promising antibody-based detection assays, Multi-Antigen Print Immuno-Assay (MAPIA), is 
based on immobilization of antigens onto nitrocellulose membranes by semi-automated 
microspraying, followed by standard chromogenic immune development. This serodiagnostic 
test uses a cocktail of multi-antigens, such as MPB83/70, ESAT-6, and CFP10 [114].   
 In a recent study, seroreactivity with MPB83 in deer was 89%; however, the MAPIA 
showed that 26% of the results were false positives in deer [115]. Based on these MAPIA results, 
a new version of an immunochromatographic test format for rapid diagnosis of MB infection, 
called rapid test (RT), was developed using colloidal gold conjugated to protein A. RT uses a 
recombinant proteins of MPB83 and TBF10 printed onto a membrane either separately as two 
bands or as a combination of the two antigens in one test line [116]. Diagnostic sensitivity of the 
RT in experimentally-infected deer was 79%, whereas that in naturally-infected deer was 67% 
[115]. Some recent studies have concluded that ESAT-6 and CFP10 (used either individually or 
as cocktail) are better candidates for diagnosis of bTB [117-119].  
 MAPIA and RT can be conducted in field and so can contribute to effective 
testing/control of bTB, especially in wild animals. However, interpretation of the test results in 
MAPIA and RT relies on observation of color development on a strip, which may vary 
depending on examiners. Higher accuracy and consistency could be achieved via a lab-free 
diagnostic device that outputs numerical data based on level of antibody binding to MB 
antigen(s). Further, as we discussed above, more efforts need to be directed towards identifying a 
better antigen (or a combination of antigens) to further improve diagnostic sensitivity and 
specificity.  
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2.5 Johne’s disease  
Johne’s disease (JD) or paratuberculosis is a chronic infectious enteritis of domestic and wild 
ruminants, causing reduction in milk production, malnutrition, weight loss and eventually death 
[120-121]. The agent is Mycobacterium avium subspecies paratuberculosis (MAP), a hardy, 
slow growing, gram-positive, and acid-fast bacteria. H. A Johne and L. Frothingham initially 
reported the disease in Germany in 1894, however, it was not until 1910 F. W. Trowt 
successfully fulfilled Koch’s postulates by growing MAP in the lab and reproducing the disease 
in experimentally infected cattle [122]. JD is prevalent worldwide and has a significant impact 
on global animal husbandry. In the US, MAP is found in 68 % of dairies [8], with average herd-
level prevalence of JD is estimated to be 22%. MAPs impact on the dairy industry in the United 
State (US) is significant, causing an estimated annual loss of $ 220 million [9].  Economic losses 
associated with JD arise from decreased milk production, reduced fertility and higher rate of 
culling [123]. In addition to the economic impact of JD to dairy industry,  it is possible that MAP 
plays a role in Crohn’s disease, which is an inflammatory bowel disease in humans  [124].  
These economic and possible health concerns create an urgent need for improved control of JD.  
As no practical treatment is available for JD, a better understanding of the transmission, 
detection and management of the disease are the recommended procedures for its control [125]. 
Epidemiological studies of MAP have been hampered by the fact that current diagnostic tests 
suffer from lack of sensitivity and are incapable of detecting latent MAP infections. 
 Diagnostic tests to detect infection with MAP can be categorized into those that identify 
the organism and those that identify the immunological response to the organism. Fecal culturing 
for MAP using Herrold’s egg yolk medium (HEYM) has been considered as a gold-standard test 
for JD diagnosis; however, it takes as long as 16 weeks to see an observable growth. Other 
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approaches, such as the use of BACTEC radiometric liquid culture [126-127] and MGIT culture 
medium [128], have been examined to reduce the culture time but these approaches require a 
specialist and are relatively expensive. Polymerase chain reaction (PCR) based diagnosis using 
IS900 insertion sequence [129] or F57 DNA fragment [130], on the feces of suspect animals can 
also be used. This PCR-based approach is much faster but is less sensitive than the culture test 
because PCR reaction can be inhibited by substances in the feces. Animals develop both CMI 
and humoral responses against MAP. CMI responses in the early stages of JD include 
recruitment and proliferation of CD4+ Th1 cells, CD8+ cells, and peripheral blood mononuclear 
cells. The recruited immunocytes secrete high levels of cytokines, including IFN-γ, which can be 
detected serologically. In late stage of JD, a shift from the CMI to humoral response (antibody 
production) is generally observed [131-132]. A CMI-based diagnostic test, the IFN-γ assay, has 
been evaluated using blood samples of experimentally-infected cattle. The study demonstrated 
that the IFN- γ assay could detect MAP infections in early stage of JD [133-134]; however, IFN- 
γ assay is affected by antigen stimulation and blood sampling - storage conditions [135-136]. 
This suggests that the IFN-γ test requires further optimization.  
 Three different tests are used to measure antibody response in JD – complement fixation, 
agar gel immunodiffusion, and ELISA.  The complement fixation and agar gel immunodiffusion 
tests both suffer poor sensitivity [137], and so a recent report has suggested that ELISAs are the 
best of the three methods for controlling JD in dairy and beef herds [125].  Diagnoses of JD 
using ELISA have been reported in many previous studies using different antigens [134, 138-
148]. The antigens used in these studies have used protoplasmic antigen (PPA) [140-143, 145, 
147], lipoarabinomannnan (LAM) [138], culture filtrate of MAP [146] and MAP proteins – 1152 
and 1156 [148] for testing antibodies against MAP. Beam et al. (1969) described a crude antigen 
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mixture termed PPA, which is prepared by thorough physical disruption of mycobacterial bacilli 
followed by removal of cell debris and cell wall components [149].  Although many 
investigators have prepared PPA using various preparation protocols, it contains proteins very 
similar to proteins commonly found in closely related mycobacteria species. LAM is one of the 
components of the cell wall of mycobacteria species [108] and its core structure is shared among 
mycobacterial species [150].  
 Sweeney et al., (1994) tested milk and serum samples in a LAM-based ELISA to detect 
antibodies for JD diagnosis and found that sensitivity and specificity of the ELISA were similar 
regardless of the tested samples (i.e. milk and serum) [138]. McKenna et al., (2005) compared 
diagnostic performance of PPA-based ELISA and LAM-based ELISA using fecal culture test as 
a gold standard.  Sensitivity and specificity of the PPA-based ELISA were higher than that for 
the LAM-ELISA [151]. PPA and LAM both contain structures common in mycobacterial species, 
so the use of these molecules as diagnostic antigen can cause false positive reactions in animals 
infected with environmental mycobacteria other than MAP [152].  
 Bannantine et al., (2008) tested 18 purified recombinant proteins in ELISA format for 
serodiagnosis of ovine paratuberculosis. They found that MAP proteins 0862 and 3786 
demonstrated the strongest antibody response and MAP protein 2116c the weakest [153]. Shin et 
al. (2008) used culture filtrate of a MAP strain, JTC, in ELISA format for JD diagnosis and 
named the method JTC-ELISA [146]. JTC-ELISA showed significantly higher sensitivity than 
that of commercial ELISA tests and performed effectively on both serum and milk samples. As 
mentioned above that the recommended control measure for JD is testing herds by ELISA 
methods but the current ELISA tests have low sensitivity (28 – 44.5%) [142].  We have 
previously reported that the surface antigens of MAP are capable of detecting anti-MAP 
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antibodies in serum at early stages of JD [154-157] and developed an ELISA for JD, named 
ethanol vortex ELISA (EVELISA).  The results from EVELISA showed that 97.4% of the JD 
positive samples had higher antibody binding levels than those of JD negative samples [156-157].  
 ELISA, as well as other methods for JD diagnosis, needs to be conducted in diagnostic 
laboratories employing staff with expertise in microbiology, molecular biology, and immunology. 
This requires a labor-intensive process involving collecting samples into proper containers, 
indexing, packing, and shipping.  Furthermore, cost per sample is relatively high -- testing a 
sample by current fecal culture, PCR, and ELISA tests cost $16-19, $25 and $5-6, respectively, 
and this does not include costs associated with site visits and sample collections and shipping 
[125].  Because of the labor and cost for the current JD diagnosis, screening of cattle herds for 
JD is generally conducted at an interval of 6 – 12 months.  During this interval, non-shedding 
animals can become shedders and low-shedding animals can become high shedders, thereby 
spreading MAP infection widely in the herd. This relatively long time interval between JD 
screening tests, in combination with low sensitivity of current diagnostic tests, may have been a 
reason that MAP infections remain so widespread in the U.S. dairy and beef industries.  
 Controlling JD requires a better understanding of the spread of MAP in a dairy herd, 
which can be achieved by continuous monitoring of the infection using a lab-free diagnostic 
device. For development of a lab-free diagnostic device, microfulidic technology has begun to be 
employed in the last decade [14]. Microfluidic devices are state-of-the-art tools for biochemical 
and immunological analysis that have high sensitivity, require only short periods of time, small 
amounts of reagents and do not require an expert operator [13, 15, 158]. In our recent study, we 
developed a prototype of lab-free diagnostic device for JD by using a microfluidic technology 
and the antigen used in the EVELISA test [159]. The major advantages of this system are its low 
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cost,  ultraportable and disposable immunoreactions chip, and the ability to detect antibodies 
within 20 min [159].  
 
2.6 Conclusion 
As discussed above, current serodiagnosis for TB, bTB and JD suffers low sensitivity and/or 
false positive reactions (causing low specificity), arising from the potential exposure of tested 
individuals other nonpathogenic environmental bacteria. Recent studies have indicated that the 
use of multiple antigens may improve diagnostic accuracy of the serodiagnosis of the 
mycobacterial diseases. Most recent efforts to develop improved serodiagnostic tests have 
focused on protein antigens. Since mycobacteria are known to produce a variety of species-
specific lipidic molecules, efforts to identify lipidic diagnostic antigens could be a particularly 
useful contribution to the development of more specific tests for TB, bTB and JD.  Accurate lab-
free diagnostic devices would be valuable in understanding the epidemiology of the 
mycobacterial infections and would facilitate their control. The emergence of new technologies 
such as microfluidics and ‘Lab-on-Chip’ hold considerable promise for accelerating the 
development of lab-free diagnostic devices for these mycobacterial infections.  
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3.1 Abstract 
Johne’s disease (JD) or paratuberculosis, caused by Mycobacterium avium ssp. paratuberculosis 
(MAP), is one of the most widespread and economically important diseases of livestock and wild 
ruminants. Control of JD could be achieved by good herd management practices and diagnosis; 
however, this approach has been hampered by the fact that the currently available commercial 
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diagnostic tests suffer low sensitivity. In our previous study, we developed a sensitive serum 
ELISA test, named EV (ethanol-vortex) ELISA using surface antigens of MAP extracted by a 
brief agitation of the bacteria in 80% ethanol using a vortex mixer. The objective of this study is 
to demonstrate that the EVELISA can be used for detection of anti–MAP antibodies in milk 
samples. In this study, we tested and optimized concentrations of antigen, milk, and secondary 
antibody for better differentiation of milk samples of cattle with MAP infections from those of 
cattle in JD–free herds. We evaluated five environmental mycobacteria as absorbents of cross 
reactive antibodies in milk and found that the mycobacteria had no significant effect on 
EVELISA results. Using the optimized conditions, a total of 57 milk samples from Holstein 
dairy cattle (37 animals found positive on the fecal PCR test and 20 animals from JD-free herds) 
were tested for anti-MAP antibody in milk by using the EVELISA method. The average of 
ELISA values in the JD-positive milk samples (mean ± SD = 0.355 ± 0.455) was significantly 
higher than that in the JD-negative milk samples (mean ± SD = 0.071 ± 0.011).  These results 
warrant further studies for evaluation and validation of the EVELISA for milk testing of cattle 
for JD.   
 
Key Words: Mycobacterium avium ssp. paratuberculosis, Johne’s disease, milk, ELISA. 
 
3.2 Introduction 
Johne's disease (JD), caused by Mycobacterium avium ssp. paratuberculosis (MAP), is a chronic 
infectious enteritis of domestic and wild ruminants. The disease is economically very important 
causing a loss of 200- 250 million US dollars annually to the US dairy industry (Ott et al., 1999). 
A regression model estimated that economic losses caused by JD in dairy farms is in the range of 
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$40 to $227 per cow per year (Ott et al., 1999). Most of the economic losses associated with JD 
are related to decreased milk production, reduced fertility and higher rate of culling (Nordlund et 
al., 1996). In addition to the economic impact of JD to dairy industry, a number of reports 
suggested a possible role of MAP in the inflammatory bowel disease in human, Crohn’s disease 
(Wynne et al., 2011).  Also, some recent reports suggested a link between MAP infections and 
type-I diabetes (Cossu et al., 2011; Sechi et al., 2008). Since MAP bacilli were found in dairy 
products (Ayele et al., 2005; Ellingson et al., 2005) and meats (Alonso-Hearn et al., 2009), it is 
important to control JD to avoid the potential human health concerns caused by MAP. A recent 
report recommended that ELISA should be used for controlling the disease in dairy as well as 
beef herds (Collins et al., 2006). However, current ELISA tests were reported to have low 
sensitivity (28 – 44.5%) (Collins et al., 2005).  We previously reported that the surface antigens 
of MAP are capable of detecting anti-MAP antibodies in serum at early stages of JD (Eda et al., 
2006; Eda et al., 2005; Scott et al., 2010; Speer et al., 2006) and developed an ELISA for JD, 
named ethanol vortex ELISA (EVELISA).  The results from EVELISA showed that 97.4% of 
the JD positive samples had higher antibody binding levels than those of JD negative samples 
(Eda et al., 2006; Scott et al., 2010).   
Serum ELISA is similar to milk ELISA in terms of the testing time and cost of the assay. 
However, since milk samples from individual cows are routinely collected on dairy farms 
enrolled in the Dairy Herd Improvement Association (DHIA) testing, milk ELISA is less labor-
intensive and less invasive for testing dairy cattle as compared to serum ELISA. In this study, we 
tested if the EVELISA method can be used to detect anti-MAP antibodies in milk samples of 
dairy cattle naturally infected with MAP.  
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3.3 Materials and Methods 
3.3.1 Milk samples 
A total of 57 serum samples used in this study were obtained from two dairy herds in Michigan. 
Twenty samples were from JD negative herds (JD-negative samples) and 37 samples were from 
cattle tested positive for JD by a PCR test (JD-positive samples). Ten JD-negative and 10 JD-
positive samples were selected for optimization of ELISA conditions and the remaining samples 
were added for evaluation of the optimized condition. The details of the samples and grouping 
were described below. 
Group N1: A total of 10 Holstein cattle from a dairy herd in Michigan were included in this 
group. The herd is a level 2 status dairy herd according to the National Voluntary Johne’s 
Program. A herd is classified as level 2, if it is negative for ELISA followed by MAP detection 
test and its size is less than 100 (USDA, 2010). The animals were tested negative for JD by fecal 
PCR test (AntelBio, 2010) and ELISA (Parachek, PRIONICS, Schlieren-Zurich, Switzerland). 
The age and lactation history of the animals in this herd are not available.  
Group N2: A total of 10 Holstein dairy cattle from a dairy in Michigan were included in this 
group. The whole herd was tested negative using the PRIONICS ELISA for 2 consecutive years 
in 2008 and 2009. The animals in this group ranged from 1-2 lactations and 2-3 years of age.  
Group P1: A total of 10 Holstein dairy cattle from a dairy farm in Michigan were included in this 
group. The animals in this group were in their 1st to 3rd lactation. The age of the animals ranged 
from 4 to 5 years and they were tested positive for JD by the AntelBio fecal PCR test. The herd 
level test prevalence of this herd for JD at the time of sample collection (2009) was 8.7 %.  
Group P2: Another set of positive samples were from the same herd of Group P1 in Michigan 
but consisted of a total of 27 Holstein dairy cattle that were tested positive for JD by the 
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AntelBio fecal PCR. The animals in this group ranged from their 2nd to 7th lactation. The age of 
the animals in this group ranged from 3 to 9 years. 
3.3.2 ELISA procedures 
Commercial ELISA:  A commercial ELISA (IDEXX Laboratories, Westbrook, ME), termed 
ELISA-I in this study, was carried out according to the manufacturer’s instructions. The ELISA-I 
was approved by the US Department of Agriculture for detection of anti-MAP antibodies in milk 
samples as well as serum samples. The milk samples were tested in duplicates for the presence of 
antibodies against MAP. The ratio of optical densities of samples and positive control (S/P value) 
was determined and JD status was assigned using the cut-off S/P value of 0.40 as recommended 
in the manufacturer’s instructions.  
EVELISA:  EVELISA test was conducted as described previously (Eda et al., 2006).  In Figures 
1A-1C, different dilutions of MAP ethanol extract, milk and secondary antibody were used to 
optimize the conditions as indicated in the figures. In Figure 1D, milk samples were incubated 
(room temperature, 30 min) with heat-killed mycobacteria (2 mg/mL; M. phlei, M. chelonae, M. 
fortuitum, M. terrae, and M. flavescens provided by Dr. P. Small, Department of Microbiology, 
the University of Tennessee, Knoxville) prior to EVELISA testing in an attempt to absorb cross-
reactive antibodies in milk.  In Figure 2, the cut-off value was set as mean + 3 standard deviation 
(0.1) of the OD values obtained using the 20 negative milk samples (Groups N1 and N2).   
3.3.3 Antel Bio Fecal PCR test 
For fecal sample processing, 2 g of feces was mixed in 25 mL of 0.2N NaOH for 30 min and 
coarse sediment removed by centrifugation at 300 x g for 3 minutes. The supernatant was 
harvested through 2 layers of cheesecloth and MAP concentrated into the pellet fraction by 
centrifugation for 30 minutes at 4000 x g. After washing, the pellet (30 minutes at 4000 x g) was 
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transferred into a microcentrifuge tube and disrupted by bead beating for 2 minutes with 0.5 g 
zirconium beads (0.1 mm) in 200 µL of PBS-1 mM EDTA. The clarified supernatant after 
centrifugation at 10,000 x g for 10 minutes was diluted 1:50 in PCR-grade water prior to direct 
analysis by quantitative PCR (qPCR) described below. The DNA primer and probe combination 
for MAP qPCR was designed by Primer Express 3 software (Life Technologies, Carlsbad, CA) 
for TaqMan chemistry to recognize a 65 base pair region of the repeat element IS900 in the MAP 
genome (Acc. No. X16923). The primers and probe sequences used for target amplification and 
detection were; forward primer, GCC TTC GAC TAC AAC AAG AGC; reverse primer, GCG 
TCG GGA GTT TGG TAG; and probe with a FAM-based detection dye, GCC GCG CTG ATC 
CTG CTT ACT. Amplification efficiency during qPCR was also monitored by the inclusion of 
internal positive control DNA (IPC), plasmid pCR2.1-TOPO containing the human actin gene 
(Acc. No. NM001101.3). The primers and probe for the amplification and detection of the 55 
base pair target region of human actin were; forward primer, GCG CGG CTA CAG CTT CA; 
reverse primer, CTT AAT GTC ACG CAC GAT TTC C, and probe with a VIC-based detection 
dye, CAC CAC GGC CGA GC. The content of IPC used for qPCR was determined by titration 
and yielded cycle threshold (Ct) values of 32 ± 1. Quantitative PCR was performed in an AB 
7500 Real-time Thermocycler (Life Technologies, Carlsbad, CA) using a 25-µL reaction volume 
containing 5% bovine serum albumin. Specifically, each reaction contained 12.5 µL TaqMan 
Universal Master Mix, 0.9 µM IS900 primers, 0.9 µM IPC primers, 0.1 µM FAM-labeled probe 
for IS900, 0.1 µM VIC-labeled probe for IPC, 0.125 ng IPC plasmid DNA and 9 µL of diluted 
sample extract or controls. The qPCR reaction conditions were as follows: 1 cycle of 95°C for 10 
minutes; and 40 cycles of 95°C for 15 seconds, 60°C for 1 minute. In addition to the IPC, each 
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test panel included positive (MAP derived DNA) and negative controls in PCR-grade water. 
Samples with Ct values less than 36 are considered positive for the presence of MAP. 
3.3.4 Statistical analysis 
All experiments were conducted in duplicate or triplicate and repeated at least twice. The 
statistical difference of antibody binding among various sets of conditions and between Group 
N1 and Group P1 were evaluated by using Mann-Whitney U test, due to lack of normality in the 
distribution of the data (calculated by Shapiro - Wilk normality test).  The statistical analysis and 
depiction of box plots were conducted by using statistical software, R.   
 
3.4 Results 
3.4.1Optimization of antigen dilutions 
Antibody binding was evaluated in EVELISA test with different antigen dilutions – 1:20, 1:40, 
1:80 and 1:160. In this experiment, two groups of milk samples, Groups N1 (n=10) and P1 
(n=10), were tested in duplicates using a 1:5 dilution for milk samples and a 1:1,000 dilution for 
secondary antibody. The difference between antibody binding in the two groups was greatest (P 
< 0.001, Mann-Whitney U test) at the 1: 20 antigen dilution (Figure 1-A). For 1: 20 antigen 
dilution, the average OD values for JD positive and negative milk samples were 0.249 ± 0.068 
and 0.078 ± 0.024 (mean ± SD), respectively. Based on this result, the 1:20 dilution of ethanol-
extracted antigen was used in the following experiments.  
3.4.2 Optimization of milk dilutions 
Milk samples of Groups N1 and P1 were tested for antibody binding in the EVELISA test using 
different dilutions (1:2.5, 1:5, 1:10 and 1:20) and a secondary antibody dilution of 1:1,000. The 
greatest difference (P < 0.0001, Mann-Whitney U test) was observed at the milk dilution of 1:2.5 
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(Figure 1B); however, levels of antibody binding in JD-negative samples (Group N1) were 
higher than other dilutions.  Therefore, the milk dilution of 1:10 (P < 0.001, Mann-Whitney U 
test) was selected for the following experiments. For 1: 10 dilution of milk, the average OD 
values for JD positive and negative milk samples were 1.2 ± 0.479 and 0.195 ± 0.146 (mean ± 
SD), respectively. 
3.4.3 Optimization of secondary antibody dilutions 
Using the antigen dilution of 1:20 and milk dilution of 1:10, antibody binding was evaluated 
using different secondary antibody dilutions, 1:500, 1:100, 1:2000 and 1:4000. The difference 
between antibody binding in the Group N1 and Group P1 was greatest (P < 0.001, Mann-
Whitney U test) at a 1: 500 dilution of secondary antibody (Figure 1-C) and this dilution was 
used in the following experiment. For 1: 500 dilution of secondary antibody, the average OD 
values for JD positive and negative milk samples were 1.338 ± 0.440 and 0.303 ± 0.187 (mean ± 
SD), respectively. 
3.4.4 Comparison of different mycobacteria as absorbent 
Antibody binding to MAP antigen was evaluated in EVELISA test using different mycobacteria 
species as absorbent of cross-reactive antibodies (Figure 1-D). There was no significant 
difference between antibody binding in the Group N1 and Group P1 using unpaired t - test.  
3.4.5 Evaluation of the EVELISA for milk testing 
JD-negative milk samples (Groups N1 and N2) and JD-positive milk samples (Groups P1 and P2) 
were tested by the EVELISA using the optimized dilutions of antigen, milk and secondary 
antibody.  Out of the 37 milk samples in the Groups P1 and P2, 25 samples showed higher levels 
of antibody binding than the tentative cut-off value determined using results of Groups N1 and 
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N2 samples (Figure 2). In the same sample set, 21 samples in Groups P1 and P2 were tested 
positive for JD by using a commercial ELISA test, ELISA-I.  
 
3.5 Discussion 
Previous studies on developing milk ELISA for JD have used protoplasmic antigen (PPA) 
(Collins et al., 2005; Hendrick et al., 2005; Klausen et al., 2003; Sharma et al., 2008; Singh et al., 
2007; Wells et al., 2006), lipoarabinomannnan (LAM) (Sweeney et al., 1994), and culture filtrate 
of MAP (Shin et al., 2008) for testing antibodies in the milk of animals. PPA is a crude antigen 
mixture prepared by thorough physical disruption of mycobacterial bacilli followed by removal 
of cell debris and cell wall components (Beam et al., 1969).  It is likely that PPA contains 
proteins that are common or very similar in the closely related mycobacteria species. LAM is one 
of the components of the cell wall of mycobacteria species (Sugden et al., 1997) and its core 
structure is shared among mycobacterial species (Mishra et al., 2011). Sweeney et al. (1994) 
tested a LAM-based ELISA to detect antibodies in milk and serum for JD diagnosis and found 
that sensitivity and specificity of the ELISA were similar regardless of the tested samples (i.e. 
milk and serum).  McKenna et al. (2005) compared diagnostic performance of PPA-based 
ELISA and LAM-based ELISA using fecal culture test as a gold standard.  Sensitivity and 
specificity of the PPA-based ELISA were higher than that for the LAM-ELISA (McKenna et al., 
2005). Because PPA and LAM contains structures common in mycobacterial species, use of 
these molecules as diagnostic antigen can cause false positive reactions in animals infected with 
environmental mycobacteria other than MAP (Osterstock et al., 2007).  In a recent study, Shin et 
al. (2008) used culture filtrate of a MAP strain, JTC, in ELISA format for JD diagnosis and 
named the method, JTC-ELISA. JTC-ELISA showed significantly higher sensitivity than that of 
54 
 
commercial ELISA tests and performed effectively on both serum and milk samples.  In this 
study, we used antigens extracted from MAP bacilli by using 80% ethanol in the EVELISA for 
milk testing.  The ethanol extract was prepared by gently mixing bacteria in an ethanol solution 
for a short time period and it is likely that major components are surface antigens. We previously 
showed that the ethanol extract reacted specifically with serum samples of MAP-infected calves 
but not with those of calves infected with other species of mycobacteria (Eda et al., 2006).  In the 
ethanol extract, MAP-specific lipidic molecules were detected by thin layer chromatography 
(data not shown). Thus, the high sensitivity of the EVELISA test may be due to the reduction of 
non-specific antibody binding. Molecular characterization of the lipidic molecules in the extract 
has not yet been completed.  
Previous studies have used different dilutions of milk for ELISA – 1:20 (Shin et al., 2008), 1:10 
(Sweeney et al., 1994), 1:2 (Klausen et al., 2003; Nielsen et al., 2002; van Weering et al., 2007). 
Singh et al. (2007) and Sharma et al. (2008) used whey for testing antibodies against MAP at a 
dilution of 1:10 and 1:8 respectively. For the EVELISA, a 1:10 dilution of milk was found to be 
optimal for differentiation between JD positive and negative milk samples. Thus, the dilutions 
used in the previous studies were similar to the dilution optimized in the current study despite the 
difference of the antigens used in the ELISAs.  The secondary antibody in most of the studies 
(Collins et al., 2005; Hendrick et al., 2005; Huda et al., 2004; Klausen et al., 2003; Nielsen et al., 
2002; Sharma et al., 2008; Shin et al., 2008; Singh et al., 2007; Sweeney et al., 1994; van 
Weering et al., 2007) were diluted in the range of 1:500 to 1:4000. These dilutions are 
compatible with the dilution optimized in this study (1:500).  
In the previous studies on milk ELISA tests for JD, milk samples were  preabsorbed with 
environmental mycobacteria (M. phlei) at different dilutions before performing the assay to 
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prevent cross reaction of non-specific antibodies (Klausen et al., 2003; Nielsen et al., 2002; van 
Weering et al., 2007). In a recent study, preabsorption of serum samples improved the specificity 
of the EVELISA when serum samples were tested (Scott et al., 2010). However, in the current 
study with milk samples, there was no effect of preabsorption on differentiation of JD-positive 
and JD-negative milk samples.  The reason for this difference in serum and milk EVELISA is 
not known, but it is possible that there was no (or only a low level of) infection of cattle with 
environmental mycobacteria in the dairy farms where milk samples were collected for this study.  
There were several previous studies evaluating diagnostic performance of milk ELISA for JD 
(Collins et al., 2005; Hendrick et al., 2005; Sharma et al., 2008; Shin et al., 2008; Singh et al., 
2007; Sweeney et al., 1994; van Weering et al., 2007; Wells et al., 2006).  The sensitivity and 
specificity of milk ELISA in previous studies ranged from 26%-76.9% and 99%-100%, 
respectively.  For example, Hendrick et al. (2005) and Collins et al. (2005) reported sensitivities 
of only 40 and 28.6%. Wells et al. (2006) reported a sensitivity of only 26% for their milk 
ELISA test. Singh et al. (2007) reported a higher sensitivity for milk ELISA (76.9%). But the 
number of samples tested was only 26 and also the status of the herds from where the samples 
were collected was not mentioned.  In this study, we tested a total of 57 milk samples (37-
positive and 20-negative). Out of the 37 positive samples (see methods section for details), 25 
samples were found positive by the EVELISA test compared to 21 samples testing positive by 
ELISA-I. However, the number of samples in this study is not enough to compare diagnostic 
accuracy of the ELISA-I and EVELISA tests.  
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3.6 Conclusion 
Previous reports suggested that MAP exists in food materials and may be a cause of human 
diseases. JD control is, therefore, important for prevention of the potential food-borne diseases. 
Since milk can be obtained cost-effectively and non-invasively, a sensitive milk ELISA would 
facilitate JD control in dairy farms. Our data demonstrated that optimized EVELISA test could 
detect antibodies in JD-positive milk samples and differentiated a majority of JD-positive 
samples from JD-negative samples. This work warrants further studies to examine if a sensitive 
milk ELISA test for JD diagnosis can be developed based on the EVELISA optimized for milk 
testing.  
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FIGURE 1- Wadhwa et al. 
 
Figure 1- Optimization of EVELISA conditions for milk testing: Optimization of the different 
conditions for the milk EVELISA test were conducted by using different dilutions of antigen (A), 
milk (B), secondary antibody (C) and statistical analyses were done using Mann – Whitney U. 
Comparison of different mycobacterial species (D) was conducted for possible use as 
preaborbent of cross reactive antibodies, the values were log-transformed and then p values for 
different mycobacteria species were calculated using unpaired t – test. The open circles indicate 
outliners.  
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FIGURE 2 – Wadhwa et al. 
Figure 2 – EVELISA results on 57 milk samples: Antibody binding in 57 milk samples in 
Groups N1 & N2 (N) and P1 & P2 (P) were tested by using the optimized EVLISA test.  The 
horizontal line represents a tentative cut-off value (0.105, mean + 3 standard deviation of the OD 
values obtained using milk samples of Groups N1 and N2) for milk EVELISA test. The 4 shaded 
triangles represent milk samples that tested JD positive by milk EVELISA test but not by 
ELISA-I. All of the samples tested negative by the EVELISA test were also tested negative by 
the ELISA-I. The 3 positive samples plotted at the OD value of 1.0 showed OD values of 1.18, 
1.50, and 1.90.    
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CHAPTER 4 
 
USE OF ETHANOL VORTEX ENZYME LINKED IMMUNOSORBENT 
ASSAY FOR DIAGNOSIS OF BOVINE TUBERCULOSIS IN FARMED 
RED DEER (CERVUS ELAPHUS) 
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Running Title: 
ELISA for diagnosis of bovine tuberculosis  
 
4.1 Abstract: 
Bovine tuberculosis (bTB) has posed threat due to its presence in the wildlife species and 
possibility to spill the infection to the domestic animals. Control programs of bTB depend on 
testing and slaughtering the positive animals; however, the currently available diagnostic tests 
suffer poor specificity, due to possible confounding factors like infection and vaccination with 
Mycobacterium avium ssp. paratuberculosis (MAP). In our previous study, we developed a 
sensitive enzyme linked immunosorbent assay (ELISA), called ethanol vortex ELISA 
(EVELISA), using surface antigens of MAP by briefly agitating the bacilli in 80% ethanol 
solution. The objective of this study is to examine whether EVELISA technique could be used to 
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detect anti- Mycobacterium bovis (MB) antibodies in the serum of infected farmed red deer 
(Cervus elaphus). In this study, we tested a total of 50 red deer serum samples, divided in 4 
groups - animals uninfected with both MB and MAP (n = 15), experimentally infected with MB 
(n = 15), naturally infected with MB (n = 5) and animals vaccinated against MAP (n = 15).  The 
presence of anti-MB antibodies was tested using ethanol extract of MB. Without absorption of 
anti-MAP cross reactive antibodies, it was found that 13 out of the 15 animals vaccinated for 
MAP showed high antibody binding. Using heat killed MAP as absorbent of cross reactive 
antibodies, the tentative diagnostic sensitivity and specificity of the EVELISA was estimated to 
be 90% and 93.3%, respectively. The results from this study suggest that EVELISA may form a 
basis for a sensitive and specific test for the diagnosis of bTB.  
 
Key words: Bovine tuberculosis; ELISA; Mycobacterium bovis; Red deer 
 
4.2 Introduction 
Bovine tuberculosis (bTB), mainly caused by Mycobacterium bovis (MB), is an infectious, 
chronic disease of zoonotic and economic importance. It is characterized by formation of typical 
granulomatous lesions with varying degrees of necrosis, calcification and encapsulation. 
2,11,19,21,31
 bTB has been identified in a wide range of wildlife species, domestic animals and 
humans. 20,24 Global economic loss due to bTB is estimated to be about US$ 3 billion annually. 27 
In the recent years, importance of bTB in the wildlife species has increased not only due to its 
role as potential reservoir for domestic animals but also as a threat to the wildlife. 5 In the state of 
Michigan, 633 free- ranging white tailed deer have been confirmed positive for MB infection out 
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of the 178,199 tested. 23 Since, there are no effective treatments and vaccines for bTB, 
eradication of the disease remain the only control measure.  
Effective eradication programs to control bTB focus on test- slaughter policy of the wildlife 
reservoirs and/or abattoir surveillance. 12,22  One of the major antemortem tests for bTB is the 
tuberculin skin test (TST) using purified protein derivatives (PPD). 11,18 But, the TST suffers low 
specificity and is impractical for wildlife species due to the need of recapturing - testing animals 
48 – 72 hours after the injection of PPD. 4-5 Assays like interferon-γ which measures cell 
mediated immune response have also been evaluated for bTB diagnosis. 25 But these assays 
require fresh blood samples and also have not been validated for diagnosis of bTB in wildlife 
species. 15 Antibody- based assays for detection of bTB have shown promising results due to 
their flexibility and cost effectiveness. Prior studies on development of antibody based assays 
have used cross reactive preparations of MB, such as crude cell sonicate 8, culture filtrate 26, PPD 
14
, and lipoarbinomannan (LAM) 30. Specific molecules like ESAT-6, CFP10, MPB83 and 
MPB70 have also been used for detection of anti-MB antibodies. 13,32,37 Recent studies have 
demonstrated the advantages of multi-antigen techniques, such as multi-antigen print immune-
assay (MAPIA) 35 and lateral flow rapid test (RT) 15, have been tested using cocktails of antigens 
like ESAT-6, CFP10 and MPB83. Although, these studies have shown promising results in 
detecting antibodies against MB, but their results were confounded due to presence of anti - 
Mycobacterium avium ssp. paratuberculosis (MAP) antibodies due to infection and/or 
vaccination. 3 We have previously developed a novel enzyme linked immunosorbent assay 
(ELISA), called as ethanol vortex ELISA (EVELISA) using surface antigens of MAP for 
detecting anti-MAP antibodies in serum at early stages of Johne’s disease (JD). 6-7,28-29 The aim 
of the present work was to assess the performance of EVELISA optimized to diagnose bTB 
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using serum samples from various groups of red deer (Cervus elaphus) including naturally and 
experimentally infected animals with MB and MAP.  
 
4.3 Materials and Methods 
4.3.1. Samples 
In order to evaluate the performance of EVELISA, a total of 50 red deer sera were obtained from 
4 different studies in New Zealand. Group 1 consisted of 15 deer of various ages which were not 
vaccinated or challenged with neither of MB and MAP. All the animals in this group were 
negative for MB by isolation methods using lymph node samples and also for MAP using an 
ELISA test (paralisa).16 Group 2 consisted of 15 deer of different ages which were 
experimentally challenged using 0.2 mL volume of 500 CFU of MB into the left tonsillar crypt 
of anesthetized deer. 17 From all the animals in this group, MB was isolated from gross lesions or 
pooled lymph node samples (head, thoracic or intestinal lymph nodes) after 27 weeks of 
experimental challenge. Out of the 15 samples in this group, 7 samples were positive for MAP 
using paralisa test. Group 3 consisted of 5 deer samples which were naturally infected with MB 
(confirmed by MB culture). Out of these 5 samples, 2 samples were positive for MAP using 
paralisa test. Finally, Group 4 consisted of 15 sera samples from deer vaccinated with MAP 
using a method previously described. 16 All the samples in this group were from animals sourced 
from a property with no history of bTB or paratuberculosis. MAP was isolated from all the deer 
in this group using culture method after 50 weeks post challenge and 12 out of the 15 samples in 
this group were positive using paralisa test.  
 
 
68 
 
4.3.2 Bacterial species and strains 
Virulent strain of MB (HC2005T), which was originally isolated from MB infected dairy cow, 
was cultured in Middlebrook’s 7H9 medium a with addition of 0.05% Tween 80 b,  10% oleic 
acid-albumin-dextrose-NaCl c at 370C until used for antigen preparation. For antigen preparation 
MB bacilli was harvested from stationary phase cultures, suspended in 80% ethanol and agitated 
by vortex to dislodge surface antigens. MAP (sheep strain) was kindly provided by Dr. John. P. 
Bannantine (Bacterial Diseases of Livestock Research Unit, National Animal Disease Center, 
USDA, Ames, IA).  
4.3.3 EVELISA 
Dislodged MB antigen was diluted in the ethanol solution and immobilized on wells of a 96-well 
plate by evaporation. The antigen-coated plate was incubated with 150 µL of buffer B (10 mM 
phosphate buffered saline, pH 7.0, containing 0.05v/v% Tween 20 and 10v/v% SuperBlock d) at 
room temperature for 30 min. The plate was then washed 4 times with 200 µL of PBST (10 mM 
phosphate buffered saline, pH 7.0, containing 0.05% Tween 20). Fifty µL of serum sample (with 
or without preabsorption of cross-reactive antibodies with heat-killed MAP [sheep strain, 4 
mg/mL] for 30 minutes) was then inoculated and incubated at room temperature for one hour. 
After washing the wells four times with 200 µL of PBST, each well was then inoculated with 50 
µL of horseradish peroxidase (HRP)-conjugated anti-deer immunoglobulin G (IgG) heavy and 
light chains e (diluted in buffer B), and incubated at room temperature for one hour.  After 
washing the wells four times with 200 µL of PBST, 100 µL of tetramethylbenzidine (TMB) 
solution f was used to develop color reaction according to manufacturer’s instruction and optical 
density (OD) of the solution was determined by a microplate reader g at 450 nm for 10 min after 
terminating the reaction by adding 100 µL of 2M sulfuric acid. 
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4.3.4 Statistical Analysis  
The cut-off value was estimated using 2 graph receiver operating characteristic to maximize 
sensitivity and specificity. 10 The test sensitivity was determined by dividing the number of 
EVELISA test positive animals by the total number of MB culture positive animals (Groups 2 
and 3), with the result expressed as a percentage. The test specificity was determined by dividing 
the number of EVELISA test negative animals by the total number of bTB free animals (Groups 
1 and 4), with the result expressed as a percentage.   
 
4.4 Results 
The diagnostic performance of EVELISA test to detect anti-MB antibodies in the sera of red deer 
was evaluated using ethanol extract of MB and compared with or without the use of MAP as 
absorbent of cross-reactive antibodies (Figure 3A-B). When antibody binding to MB antigen was 
evaluated without pre-absorption with MAP, MB positive samples (Groups 2 and 3) showed 
higher antibody binding levels than those of uninfected samples (Group 1), except for one 
sample in Group 2 (Figure 3A). However, the samples in Group 4 (experimentally infected with 
MAP) showed high antibody binding levels, suggesting presence of cross-reactive antibodies in 
MAP-infected animals.  
In Figure 3B, antibody binding was tested after absorbing cross-reactive antibodies with heat-
killed MAP bacilli. Antibody binding levels in groups 2-4 were significantly reduced. Using a 
cut-off value of 0.065 (determined by two-graph receiver operating characteristic analysis), the 
sensitivity and specificity were estimated to be 90% and 93.3%, respectively. Out of the 15 
animals in Group 1 (uninfected), 14 animals showed negative reaction with the EVELISA test. 
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Out of the 15 animals in Group 2 (experimentally challenged with MB), 13 animals were found 
positive by EVLISA test. Group 3 consisted of 5 animals with natural infection of MB and all of 
these animals were found positive by our test. The most significant difference was that antibody 
binding levels in Group 4 (n=15, vaccinated with MAP) were reduced to the same levels as 
Group 1 (uninfected), whereas antibody binding levels in the group was indistinguishable from 
those in MB positive groups (Groups 2 and 3, Figure 3A).  
 
4.5 Discussion 
Previous studies on developing ELISA for bTB in deer have used PPD (bovine and avian), 
MPB70 11,13,36, LAM 33-34. Griffin et al. (2004) have described the use of bovine PPD in ELISA 
format and suggested a sensitivity of 70%. They have also reported an ancillary blood test (BTB) 
which is composite test of both lymphocyte transformation assay and the bovine PPD ELISA. 
The BTB showed a high sensitivity of 94%; however, the test is a costly assay as compared to 
ELISA and is used as an ancillary test to examine TST-reactors rather than for whole herd testing. 
LAM has also been used as an antigen in development of antibody based assays and to evaluate 
antibody response kinetics on experimental inoculation but it is cross reactive to non-tuberculous 
mycobacteria. 34 Waters et al. (2005) suggested the use of purified proteins to improve the 
specificity of antibody based assays. 33 Recently, few rapid tests have been developed – MAPIA, 
RT and dual-path-platform (DPP) VetTB assay – using MB-specific antigens such as MPB83, 
ESAT6 and CFP-10 antigens. 9,15,35 Buddle et al. (2010) compared the 2 lateral flow tests – 
CervidTB STAT-PAK and DPP VetTB assay and reported specificities of 83.8% and 91.4%, 
respectively. 3 Boadella et al. (2011) reported a sensitivity of 51% and specificity of 96% for 
fallow deer using bovine PPD ELISA. They also tested DPP VetTB assay and depending on the 
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cut-off value selected, the sensitivity and specificity ranged from 62-71% and 88-95%, 
respectively. 1 Although these rapid tests show improved sensitivity and specificity, preparation 
of the highly purified recombinant proteins can be costly.  In this study, we used MB antigens 
prepared simply by agitating the bacteria in an ethanol solution. Our previous studies showed 
that ethanol extract of MAP contains MAP-specific antigens and can be used to diagnose Johne’s 
disease with high sensitivity.6 We recently showed that absorption of cross reactive antibodies in 
serum samples with Mycobacterium phlei improved specificity of the EVELISA test for Johne’s 
disease.28 This is similar to the observation in this study that specificity of EVELISA test could 
be improved by absorption of cross reactive antibodies by using environmental mycobacteria. 
After absorption of cross reactive antibodies with MAP, tentative sensitivity and specificity of 
the EVELISA test for bTB were estimated to be 90% and 93.3%, respectively. Forty out of 15 
samples from animals vaccinated with MAP (Group 4) were tested negative by the EVELISA 
test, indicating that a majority of antibodies reacting with MAP were removed by the absorption. 
Thus, this study suggested that the EVELISA could diagnose bTB in red deer with minimum 
false positive results caused by antibodies reacting with MAP, encouraging further studies to 
validate the test using a larger number of samples obtained from red deer farms.   
 
4.6 Acknowledgement: The work was supported by the following grants to S.E: Animal Health 
Board in New Zealand, University of Tennessee Research Foundation Technology Maturation 
Grants, University of Tennessee M-CERV seed grant; and graduate research assistantship to AW 
by the National Institute of Mathematical and Biological Synthesis.  
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4.7 Sources and Manufacturers:   
a. Middlebrook’s 7H9 medium, Becton Dickinson, Cockeysville, MD). 
b.  Tween 80, Fisher Scientific, Fair Lawn, NJ. 
c. Oleic acid-albumin-dextrose-NaCl Becton Dickinson, Microbiology Systems, Franklin Lakes, 
NJ. 
d. SuperBlock, PIERCE Biotechnology, Rockford, IL.  
e. Horseradish peroxidase (HRP) - conjugated anti-deer immunoglobulin G (IgG) heavy and 
light chains, Kirkegaard and Perry Laboratories, Gaithersburg, MD. 
f. Tetramethylbenzidine (TMB) solution, THERMO Scientific, Rockford, IL. 
g. Microplate reader, Model 680, BioRad, Hercules, CA. 
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Figure 3- Wadhwa et al.  
Figure 3 – Diagnostic performance of EVELISA test on 50 red deer serum samples. Antibody 
binding was tested using 50 red deer serum samples, without (A) and with (B) absorption of 
cross reactive antibodies against MAP. The samples were divided in 4 groups (1- Unvaccinated – 
unchallenged animals (n = 15); 2- Experimentally challenged with MB (n = 15); 3- Naturally 
infected with MB (n = 5; 4- vaccinated with MAP (n = 15)). Each marker represents an average 
of duplicate measurement. To estimate tentative diagnostic sensitivity and specificity of the 
EVELISA test, cut-off value of 0.65 (horizontal line) was used (B). 
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CHAPTER 5 
 
BEAD-BASED MICROFLUIDIC IMMUNOASSAY FOR DIAGNOSIS 
OF JOHNE’S DISEASE 
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the Journal of Immunological Methods.  
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Foote and Dr. Robert W. Shaw.  
 
Bead-based microfluidic immunoassay for diagnosis of Johne’s disease  
 
Ashutosh Wadhwa, Robert S. Foote, Robert W. Shaw, and Shigetoshi Eda 
 
5.1 ABSTRACT 
Microfluidics technology offers a platform for development of point-of-care diagnostic devices 
for various infectious diseases. In this study, we examined whether serodiagnosis of Johne’s 
disease (JD) can be conducted in a bead-based microfluidic assay system. Magnetic micro-beads 
were coated with antigens of the causative agent of JD, Mycobacterium avium subsp. 
paratuberculosis. The antigen-coated beads were incubated with serum samples of JD-positive 
or negative serum samples and then with a fluorescently-labeled secondary antibody (SAB). To 
confirm binding of serum antibodies to the antigen, the beads were subjected to flow cytometric 
analysis.  Different conditions (dilutions of serum and SAB, types of SAB, and types of magnetic 
beads) were optimized for a great degree of differentiation between the JD-negative and JD-
positive samples. Using the optimized conditions, we tested a well-classified set of 155 serum 
samples from JD negative and JD-positive cattle by using the bead-based flow cytometric assay. 
Of 105 JD-positive samples, 63 samples (60%) showed higher antibody binding levels than a 
cut-off value determined by using antibody binding levels of JD-negative samples. In contrast, 
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only 43-49 JD-positive samples showed higher antibody binding levels than the cut-off value 
when the samples were tested by commercially-available immunoassays. Microfluidic assays 
were performed by magnetically immobilizing a number of beads within a microchannel of a 
glass microchip and detecting antibody on the collected beads by laser-induced fluorescence. 
Antigen-coated magnetic beads treated with bovine serum sample and fluorescently-labeled SAB 
were loaded into a microchannel to measure the fluorescence (reflecting level of antibody 
binding) on the beads in the microfluidic system. When the results of five bovine serum samples 
obtained with the system were compared to those obtained with the flow cytometer, a high level 
of correlation (linear regression, r2 = 0.994) was observed. In a further experiment, we 
magnetically immobilized antigen-coated beads in a microchannel, reacted the beads with serum 
and SAB in the channel, and detected antibody binding to the beads in the microfluidic system. 
A strong antibody binding in JD-positive serum was detected, whereas there was only negligible 
binding in negative control experiments. Our data suggest that the bead-based microfluidic 
system may form a basis for development of an on-site serodiagnosis of JD. 
Key Words: Mycobacterium avium ssp. paratuberculosis, Johne’s disease, microfluidics, lab-on-
a-chip. 
 
5.2 Introduction  
Johne’s disease (JD) caused by Mycobacterium avium subsp. paratuberculosis (MAP) is 
prevalent worldwide and has significant impact on the global animal husbandry industry. For 
example, annual economic loss due to JD in US dairy was estimated to be $ 220 million (Ott et 
al., 1999). The economic concerns clearly indicate an urgent need for control of the disease. A 
recent report recommended that a serological test, called enzyme linked immunosorbant assay 
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(ELISA), should be used for controlling the disease in dairy as well as beef herds (Collins et al., 
2006). However, ELISA test needs to be conducted in diagnostic laboratories, causing 
cost/labors associated with shipment of samples and a long-time interval (6-12 months) in JD 
screening. Therefore, development of on-site (laboratory-free) diagnostic device would 
contribute to cost-effective JD diagnosis and control. 
Microfluidic devices are state-of-the-art tools for biochemical and immunological analysis that 
have high sensitivity and require only short periods of time and small amounts of reagents 
(Whitesides, 2006).  Because of these advantages, microfulidic technology has been used for 
development of immunoassays for on-site diagnosis of various diseases (Ng et al., 2010). 
However, to date, there is no report for development of microfluidic system for diagnosis of JD. 
In this study, we examined whether a bead-based microfluidic system can be used to diagnose JD 
by detecting specific serum antibodies in animals infected with MAP.  
 
 
 
 
5.3 Materials and methods  
5.3.1. Bacterial strains and isolates 
The Linda strain of Mycobacterium avium subsp. paratuberculosis (MAP) was obtained from Dr. 
John P. Bannantine in the United States Department of Agriculture (Ames, IA) and was cultured 
in Middlebrook 7H9 medium (Becton Dickinson Microbiology Systems, Franklin Lakes, NJ) 
with 10% oleic acid-albumin-dextrose-NaCl (Becton Dickinson Microbiology Systems, Franklin 
Lakes, NJ) and 2 mg/L of mycobactin J (Allied Monitor, Fayette, MO). The cultures were 
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maintained at 37°C without shaking until they reached an optical density of approximately 0.7 at 
600 nm.   
 
5.3.2. Serum Samples 
5.3.2.1. Group I:  
Four serum samples were obtained from female Holstein cattle (2.8-5.0 years old) in a dairy farm 
in Minnesota. Two of the four cattle (ID 11 and 167) were tested positive for JD by a 
commercial ELISA test (IDEXX, Westbrook, ME) and fecal culture test at the US Department of 
Agriculture (Ames, Iowa).  The other two cattle (ID 7 and 18) were tested negative for JD by the 
two diagnostic tests.   Also, fetal bovine serum (FBS, Thermo Scientific, South Logan, UT) was 
used as a negative control. 
5.3.2.2. Group II: 
One hundred fifty five serum samples (50 µL each) were kindly provided by Dr. Michael Collins, 
University of Wisconsin Madison. These samples were classified as JD-negative animals (N, 
n=50), low shedders (L, n=35), medium shedders (M, n=35), and high shedders (H, n=35) as 
described previously (Collins et al., 2005). MAP-infected animals shed MAP organisms in their 
feces and the level of shedding (low-high) increases as JD progresses (Sweeney, 2011).  These 
samples were tested by three commercial ELISA tests (IDEXX [ELISA-A], Biocor [ELISA-B] 
and Pouquire [ELISA-C]) (Collins et al., 2005). All serum samples were separated into aliquots 
of 20 to 1,000 µL and stored at -20 0 C for short-term storage (< 6 months) or at -80 0 C for long-
term storage (> 6 months). 
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5.3.3. Secondary antibodies 
Three different  types of secondary antibodies - goat anti-bovine IgG (H+L) conjugated with 
DyLight488 (SAB1), goat anti-bovine IgG (H+L) conjugated with FITC (SAB2) and goat anti-
bovine IgG1 conjugated with FITC (SAB3)  - were obtained from Jackson Immuno Research Inc. 
(West Grove, PA)  and used to label antibodies bound to MAP antigen. 
5.3.4. Magnetic micro-beads 
Four different types of magnetic beads – 2.74 µm plain polystyrene surface beads (BEAD1), 5 
µm plain surface beads (BEAD2), 2 µm COOH-surface beads (BEAD3) and 2 µm NH3-surface 
beads (BEAD4) obtained from Spherotech Inc. (Lake Forest, IL) and were used to immobilize 
MAP antigen. 
5.3.5. Preparation of MAP antigen coated magnetic beads and off- chip antibody binding assay 
MAP bacilli (100 µL of confluent culture) cultured in the Middlebrook’s medium were harvested 
in a microfuge tube and centrifuged at 3500 xg for 10 minutes. The bacterial pellet was 
suspended in 80% ethanol solution at 80 mg wet weight of bacteria/ml, agitated by using a 
vortex mixer and centrifuged at 10,000 xg for 10 minutes. The supernatant (ethanol extract) was 
used as MAP antigen. The antigen was coated on the surface of magnetic beads (400 µL) by 
incubating the beads with 400 µL of the ethanol extract for overnight at room temperature.  After 
washing with PBS (phosphate-buffered saline [pH 7.0]), the antigen-coated beads were 
incubated with 400 µL of buffer B (PBS containing 10 % SuperBlock [PIERCE Biotechnology, 
Rockford, IL] and 0.05 % Tween 20 [ACROS Organics, Morris Plains, NJ]) to block uncoated 
surface. The antigen-coated beads were then incubated with bovine serum (50 µL, diluted in 
buffer B) for 30 min at room temperature, washed twice with 200 µL of buffer B, and incubated 
with SAB (50 µL, diluted in buffer B) for 30 min at room temperature. After the reactions, 
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magnetic beads were subjected to analysis of antibody binding using a flow cytometer or 
microfulidic system as described below. The schematic of this procedure is presented in Figure 4. 
5.3.6. Flow cytometric method (FCM) for analysis of antibody binding  
 After the antigen coating and antibody binding described above, magnetic beads were suspended 
in 1ml of PBS and loaded to a flow cytometrer (LSR II, BD Bioscience, San Diego, CA) for 
analysis of antibody binding. On the flow cytometer, photomultiplier tube voltages were set to 
691 eV for forward scatter channel, 307 eV for side scatter and 590 eV for FL1 channel. The 
threshold was set at 200 on side scatter channel. Data of mean fluorescent (FL1) intensity 
(proportional to the level of antibody binding) were collected for 10,000 beads and analyzed by 
using DiVa software (BD Bioscience).  
5.3.7. Microfluidic system  
Microfluidic chips were fabricated as described previously (W. H. Ko, 1989; Jacobson et al., 
1994).  Briefly, a microchannel (100 µm deep x 200 µm wide at half-depth x 4 cm long) was 
etched in glass substrates (White Crown B-270; Telic, Santa Monica, CA) by photolithography 
and chemical wet etching, followed by bonding to a glass coverplate to enclose the channels.  
Access to the ends of the channel was provided by holes (2 mm diameter, ~5 µl capacity) drilled 
in the etched substrate prior to bonding the coverplate.  As shown in the schematic of Figure 5, a 
permanent magnet (neodymium disk magnet, 1/2 “diameter x 1/16” thick, K&J Magnetics) was 
placed on the top of the microchip to attract magnetic beads in the microchannel.  The proximal 
edge of the magnet was placed 1.0 cm from the entrance to the channel.  A single layer of black 
electrical tape was placed between the magnet and the microchip to prevent light reflection from 
the magnet surface.  Suspensions of magnetic beads or reagents were pipetted into the microchip 
addition port and allowed to flow into the channel.  Optionally, a microsyringe can be attached to 
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the exit hole to draw fluids into the channel.  Magnetic beads were found to collect as a closely-
packed layer (Figure. 7) on the upper surface of the channel directly under the proximal edge of 
the magnet and remained stably immobilized during subsequent washing and reagent addition 
steps.  Fluorescence from the magnetic beads was detected using a confocal optical system 
(Figure. 5) comprising a 10x objective and Nikon filter cube for fluorescein excitation/emission.  
The 488nm line from a 100W argon ion laser was used for excitation.  The microchip was 
mounted on an x-y translation stage (not shown) to adjust the position for optimum excitation of 
the immobilized beads.  Emitted fluorescence was collected with the objective, passed through 
the dichroic mirror of the filter cube and further filtered spatially (1mm pinhole filter) and 
spectrally (488 notch filter and bandpass filter) prior to detection with a photomultiplier tube 
(PMT). Electrical signals from the PMT were amplified and analyzed by LabView software 
(National Instruments, Austin, TX).  Images of fluorescence on the magnetic beads were 
captured using a Nikon TE300 inverted microscope equipped with a 10X objective, FITC filter 
cube and CCD camera (model TE/CCD, Princeton Instruments).  IPLab Spectrum software 
(Signal Analytics) was used for camera control and image processing. 
 
 
 
5.3.8. Detection of antibody binding in the microfluidic system 
5.3.8.1. Off-chip protocol: 
Antibody binding to antigen-coated magnetic beads was conducted off-chip as described above. 
The chip microchannel was first filled with PBS and aliquots (5 µl) containing approximately 
1.5*107 treated beads were then loaded into the microchannel and immobilized in the channel 
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using a permanent magnet. Fluorescence associated with the beads was quantified using the 
fluorescence detection system described above.  For comparison of samples the same 
approximate number of beads was used for each assay.  Because the focused laser beam 
interrogates only immobilized beads within the focal spot in the channel, the assay should not be 
sensitive to variations in the number of beads introduced into the channel, provided that 
sufficient beads are used to fill the focal spot in each assay.  The microchannel was rinsed to 
remove beads after each assay and refilled with PBS before adding the next sample.  
5.3.8.2. On-chip protocol: 
 After immobilizing antigen-coated magnetic beads in the channel, serum sample (Group I, cow 
ID 11, 1:20 dilution in buffer B) was loaded into the channel by passive flow. After 30 min 
incubation, PBS containing 0.05% Tween 20 was loaded into the channel to remove antibodies 
that did not bind to the magnetic beads. SAB 1(1:100 dilution in buffer B) was then loaded into 
the microchannel and unbound antibodies were removed by loading PBS containing 0.05% 
Tween 20 into the channel. After the reaction, fluorescence associated with the beads was 
quantified by the fluorescence detection system described above.  
 
 
 
5.4 Results 
5.4.1. Optimization of assay conditions in FCM 
Antibody binding to MAP antigen-coated beads was evaluated in the FCM assay with different 
dilutions of serum (1: 20, 1: 50 and 1:100) and secondary antibody (1: 20, 1: 50 and 1:100). In 
this experiment, we used 2 µm plain surface magnetic beads (BEAD1) and goat anti-bovine IgG 
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(H+L) conjugated with DyLight488 (SAB1). The difference of antibody binding between JD-
negative and JD-positive samples were found greatest with the combination of 1:20 serum 
dilution and 1: 100 secondary antibody dilution (Figure 6-A).  In the following experiment, the 
serum samples (1:20 dilution) were tested for antibody binding using different types of 
secondary antibodies (SAB1, SAB2 and SAB3, 1:100 dilution). The greatest difference of 
antibody binding between JD-negative and JD-positive samples was observed with SAB1 
(Figure 6-B) and this secondary antibody was used in the following experiments. Using the 
optimized dilutions and secondary antibody, antibody binding was evaluated using different 
types of magnetic beads (BEAD1, BEAD2, BEAD3 and BEAD4). The greatest difference 
between antibody binding levels in JD-negative and JD-positive samples was observed when 
BEAD1 was used for the assay (Figure 6-C).  
 
5.4.2. Estimation of sensitivity and specificity of the bead-based antibody binding assay in FCM 
By using the optimized assay conditions, 155 bovine serum samples were tested in the FCM. A 
cut-off-value was determined as mean + 2 standard deviation of data obtained with 50 JD-
negative serum samples. Using the cut-off value, specificity of the assay was estimated to be 
98.0%.  Estimated sensitivities were 45.7, 48.6 and 85.7 % for low, medium and high shedders, 
respectively (Table 1). The estimated sensitivities were higher than those of commercial ELISA 
tests, especially in low shedders (45.7% versus 5.7-17.1%). 
5.4.3. Detection and quantification of antibody binding in a microfulidic system  
To examine if antibody binding can be detected in a microfulidic system, antigen-coated 
magnetic beads (BEAD1) reacted off-chip with bovine serum and secondary antibody (SAB1) 
were loaded in to a microchannel and fluorescence associated with the magnetic beads was 
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observed under a fluorescent microscope.  Magnetic beads reacted with a JD-positive serum 
showed a higher level of fluorescence than that in beads treated with a JD-negative sample 
(Figure 7). The relative fluorescent intensity of the samples was determined by measuring the 
average pixel brightness in equivalent regions of interest (ROIs, green rectangles in Figure 7). 
The reacted beads were also analyzed using the detection system of Figure. 5, as described in 
Materials and Methods.  Higher levels of fluorescence were observed in this system on beads 
treated with a JD-positive serum (1:20 and 1:50 dilution) when compared with those of beads 
treated with JD-negative serum or no serum (Figure 8A). In a separate experiment, antigen-
coated beads were treated off-chip with JD-positive serum sample (n=2), JD-negative sample 
(n=2), or fetal bovine serum and subjected to the fluorescence quantification in the microfulidic 
system and FCM.  A strong correlation (r2=0.994) was observed between the results of the 
microfluidic system and FCM (Figure 8B), suggesting that the microfluidic system has a 
comparable analytical sensitivity as the FCM. In the following experiment, we examined if 
antibody binding can be detected after conducting on-chip antibody reactions. Antigen-coated 
beads were loaded into a microchannel, immobilized in the channel with a permanent magnet, 
and reacted sequentially with serum (JD-positive, JD-negative, or fetal bovine serum) and 
secondary antibody. As shown in Figure 9, significantly higher fluorescence intensity was 
observed on the beads treated with JD-positive serum than those treated with JD-negative or fetal 
bovine serum samples.  
 
5.5 Discussion  
Microfluidic immunoassay device possesses remarkable features such as high surface-to-volume 
ratio and nanoliter volume of microchannel. Microchannel can serve as immunoreactor chamber 
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that leads to significant decrease in analysis time from hours to minutes and with minimal 
sample/reagent utilization as compared to microwell technology (Terence G. Henares et al., 
2008). To further increase the size surface area for antibody reaction, microbeads have been used 
in microfluidic immunoassays (Lim and Zhang, 2007).  Also, microbeads can be washed out of 
the microchannel after antibody binding reactions and make a microfulidic immunoassay system 
reusable. Furthermore, by using a set of microbeads coated with different antigen, a single 
microfulidic system can be used to diagnose different diseases. Based on these advantages, we 
elected to use magnetic microbeads in this study.  
 
Magnetic microbeads were coated with MAP antigens extracted from MAP bacilli by using 80% 
ethanol. We previously showed that MAP surface antigens can be used to diagnose JD with 
higher sensitivity than that of commercial ELISA tests and that such antigen can be extracted by 
80% ethanol (Eda et al., 2005; Eda et al., 2006; Speer et al., 2006; Scott et al., 2010). The 
antigen-coated beads were then treated with bovine serum samples and the optimal serum 
dilution was found to be 1:20. This dilution is much lower than that (1:100) used in our previous 
study on ELISA test developed using the ethanol extract of MAP (Eda et al., 2006; Scott et al., 
2010). The optimized dilution for SAB (1:100) was also lower than the dilution (1:500) used in 
the previous study (Eda et al., 2006; Scott et al., 2010). These differences in optimal dilutions 
may be due to the fact that sensitivity of ELISA (based on enzyme reaction) is generally higher 
than that of fluorescence-based detection.  
 
Among the three SABs tested in this study, anti-IgG (H+L) antibody conjugated with 
DyLight488 (SAB1) showed the greatest level of antibody binding (fluorescence intensity) 
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compared to that of anti-IgG (H+L) antibody labeled with FITC (SAB2). The relatively new 
fluorescent dye (DyLight488) is claimed to be brighter and photoresistant than FITC and, 
therefore, the difference between the results of SAB1 and SAB2 is likely attributed to the 
property of the fluorescent dye.  The anti-IgG1 antibody labeled with FITC (SAB3) showed 
lower antibody binding (fluorescence intensity) than SAB2 (anti-IgG [H+L] antibody that binds 
to all immunoglobulin classes and subtypes), suggesting that a significant amount of 
immunoglobulin molecules other than IgG1 binds to the MAP antigen. 
  
Using the optimized dilutions and SAB, four different types (size and surface modifications) of 
magnetic beads were tested in this study. After antibody reactions, the 5-µm beads with plain 
surface (BEAD2) showed higher fluorescence intensity than 2-µm beads with plain surface 
(BEAD1); however, the difference between JD-negative and JD-positive samples was more 
significant in BEAD1. The higher fluorescence intensity is likely due to the larger surface area of 
BEAD1 since the FCM quantifies fluorescence intensity of each beads. Since fluorescence on 
islands of immobilized magnetic beads (but not each bead) is quantified in our microfluidic 
system, BEAD1 is a preferable option than BEAD2. In comparison of BEAD1 with BEAD3 (2 
µm beads with amino groups on their surface) and BEAD4 (2 µm beads with carboxyl groups on 
their surface), BEAD1 showed the greatest differentiation between JD-negative and JD-positive 
samples.  This indicates that the functional groups on the surface of BEAD3 and BEAD4 caused 
immobilization of MAP antigens that nonspecifically react with antibodies in the JD-negative 
sample.  
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By testing 155 serum samples from JD-negative and JD-positive samples using the bead-based 
assay in FCM, higher sensitivities were observed in JD-positive samples (low, medium and high 
shedders), especially in low shedders. This observation is similar to our previous study with the 
ELISA tests developed using ethanol extract of MAP; however, overall sensitivity of the bead-
based assay (60.0%) was lower than that of the ELISA test (97.4%) (Eda et al., 2006). A 
different set of samples were used in this and previous studies and, therefore, direct comparison 
of the sensitivities would not be appropriate. Also, it is possible that different properties of the 
surface of the magnetic beads (plain polystylene) and ELISA plate (polystylene treated for 
higher binding of molecules) caused a difference in amount and/or kind of antigens immobilized 
onto the surface of the beads and plate.  
 
Using the microfluidic system developed in this study, we showed that antibody binding to 
MAP-antigen-coated magnetic beads can be detected after off-chip and on-chip antibody 
reactions. Magnetic bead-based microfuidic systems have been used for development of 
immunoassays for diagnosis of diseases (GIJS et al., 2010). For example, Lee et al. immobilized 
dengue virus on magnetic beads to detect anti-dengue virus antibody in serum samples (Lee et al., 
2009). The system is fully automated and could detect antibodies in 30 min. However, there has 
not been a report describing development of microfluidic system for JD. Our results suggest that 
the microfulidic system developed using ethanol extract of MAP may form a basis for 
development of on-site diagnostic device for JD. 
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Figure 4. Wadhwa et al.  
 
Figure 4. Schematic for immunofluorescence assay using magnetic beads 
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Figure 5.  Wadhwa et al.  
 
Figure 5.  Schematic for the microfluidc system used in this study.  The microchip channel is 
filled with buffer solution.  Suspended beads are added to a channel port and migrate through the 
channel to accumulate under the magnet, where they can be imaged by fluorescence microscopy 
or semi-quantified by laser-induced fluorescence.  
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Figure 6. Wadhwa et al.  
 
Figure 6. Results from the optimization of different conditions for bead-based FCM assay by 
using different dilutions of serum and SAB (A), different types of SAB (B) and different types of 
magnetic beads (C). The bars represent antibody binding levels in fetal bovine serum (open bar), 
JD-negative (hatched bar, Group I sample, cow ID 18) and JD-positive serum (solid bar, Group I 
sample, cow ID 11) samples. Each bar represents mean ± standard deviation of triplicate 
determinations. Each experiment was repeated twice with similar results. 
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Figure 7:  Wadhwa et al. 
 
Figure 7:  Fluorescence images of immobilized immunoassay beads prepared from JD-negative 
(A, Group I sample, cow ID 18) and JD-positive (B, Group I sample, cow ID 11) samples.  The 
CCD images were taken using a Nikon TE 300 inverted microscope with 10x objective and 
FITC fluorescence filters.  Total pixel values in the identically-sized regions of interest (ROI, 
green outline) were corrected for differences in background and used to measure the relative 
fluorescence of the negative and positive beads. 
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Figure 8. Wadhwa et al. 
 
Figure 8. Results from FCM and microfluidics. (A) The results of the assays for three 
representative serum samples are shown as red - JD-positive serum (1:20 dilution, Group I 
sample, cow ID 11), blue - JD-positive serum (1:50 dilution, Group I sample, cow ID 11), green 
line - JD-negative serum (1:20 dilution, Group I sample, cow ID 18) and black line - no serum. 
(B) The results were compared with the antibody binding levels determined by the microfluidic 
system and FCM. Group I serum samples were used in this experiment - JD pos 1: cow ID 11; 
JD pos 2: cow ID 167; JD neg 1: cow ID 7; JD neg 2: cow ID 18 and FBS: fetal bovine serum. 
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Figure 9. Wadhwa et al. 
 
Figure 9. Antibody binding in the microfluidic system using on-chip antibody reaction protocol. 
Fluorescence of immobilized antigen-conjugated magnetic beads after on-chip incubation with 
antibody-containing JD-positive serum only (black line, Group I sample, cow ID 11), secondary 
only (red, SAB1), or the JD-positive serum followed by the secondary antibody (blue). 
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 Specificity (%) Sensitivity (%) 
 
N L M H 
Beads 98 45.7 48.6 85.7 
ELISA-A 100 2.9 45.7 80.0 
ELISA-B 100 17.1 42.9 80.0 
ELISA-C 100 5.7 42.9 74.3 
 
Table 1. Wadhwa et al.  
 
Table 1. Comparison of sensitivity and specificity of the bead-based assay with those of 
commercial ELISA tests (ELISA-A~C).  Serum samples (Group II) obtained from JD-negative 
animals (N, n=50), low shedders (L, n=35), medium shedders (M, n=35), and high shedders (H, 
n=35) were tested for antibody binding by different serological tests.  
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CHAPTER 6 
 
CONCLUSIONS AND OUTLOOK 
 
This dissertation provides an in-depth analysis on the current status of diagnostic techniques for 
mycobacterial infections. Mycobacterial species are ubiquitous in nature and infect a wide 
variety of hosts. The infections caused by mycobacterial species are chronic in nature and it 
requires an early diagnosis. Control measures also require an understanding of the epidemiology 
of the agent and continuous surveillance of the host species. Previous studies on diagnosis have 
used various diagnostic approaches – bacterial culture, nucleic acid amplification assays and 
quantification of the immune responses. Each approach is unique and has its advantages and 
disadvantages; however, it is well established that the development and validation of the novel 
diagnostic tests is very challenging. The reasons being long incubation period, unpredictable 
disease progression, possible infection with closely related strains and use of different specimen 
often with low bacterial load.  Present diagnostic tests suffer with drawbacks of lack of 
sensitivity – specificity, need for re-testing, higher cost and long turnaround time (up to 16 
weeks) of the agent. The major focus of our project was to access the role of surface antigens of 
mycobacterial species in detection of humoral response using different specimens (milk and 
serum) and diagnostic formats (enzyme linked immunosorbant assay {ELISA} and lab-on-a-
chip{LOC}). This study presents the results from optimization of serum based ethanol vortex 
ELISA (EVELISA) for milk testing of Johne’s disesease (JD) caused by Mycobacterium avium 
subspecies paratuberculosis (MAP), development of a serum based EVELISA for testing of 
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bovine tuberculosis (bTB) in red deer and progress in formation of a bead-based microfluidic 
immunoassay for diagnosis of JD.   
The use of ELISA has been recommended in previous studies to control JD. But the present 
ELISAs suffer with poor sensitivity. Most of these ELISA tests are based on detection of 
antibodies in the serum. Regular checking of antibodies present in serum is a tedious and costly 
process since it requires bleeding the animals and visit of veterinarians to farm. Testing of milk 
becomes more practical as it is collected on regular basis by the dairy herd improvement 
associations. Thus, we optimized a previously developed serum based ELISA based on surface 
antigens in ethanol solution to be used for milk testing (Chapter 3). By testing a set of well 
characterized milk samples, it was found that the EVELISA test was better than the 
commercially available ELISA. The results from this study showed that EVELISA could detect 
more animals which were actually positive and were showing a negative reaction by the 
commercial ELISA test.  By utilizing milk based EVELISA test, better screening of the animals 
would be possible, reducing the spread of infection with in the herd.  
Developed nations have eradicated bTB from their domestic animals but the wildlife species is 
still infected with the Mycobacterium bovis (MB). Domestic livestock population is in 
continuous contact with the wildlife species which acts as reservoir for MB and can spill over the 
infection to them. It becomes very important to have a highly sensitive – specific diagnostic test 
for bTB. Prior to this study, many diagnostic tests have been developed for bTB but they suffer 
with poor sensitivity as well as specificity. Co-infection with MAP has been previously 
described as a confounding factor for detection of antibodies in animals infected with MB. In this 
work, ethanol extract from MB was used to develop a sensitive – specific test for diagnosis of 
bTB in red deer (Chapter 4). We found that by using heat killed MAP to absorb cross reactive 
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antibodies; EVELISA can detect anti-MB antibodies. Therefore, ELISA test based on surface 
antigens from MB in ethanol solution can form a basis for a highly sensitive and specific test for 
detection of bTB in wildlife species.  
Present diagnostic tests are required to be conducted in diagnostic laboratories with expertise 
staff in molecular biology.  This involves a labor and cost intensive process requiring collecting 
samples and shipping it to the lab. Use of surface antigens of MAP and its application in 
development of LOC device for diagnosis of JD is also described in this dissertation (Chapter 5). 
Here, we provide evidence to conclude that species specific surface antigens provide better 
diagnostic advantages and could be used to form a basis for onsite diagnosis of the mycobacterial 
infections.  
Finally, to expand upon the work in this dissertation, testing of more samples to calculate 
diagnostic sensitivity and specificity should be performed with EVELISA (both for JD and bTB) 
and the bead-based onsite diagnostic format. Characterization and isolation of molecules present 
in the ethanol extract would also be important for further improvement of diagnostic accuracy. 
Recently, specific lipid molecules (e.g. Para-LP-01) have been isolated and shown to be useful in 
detection of antibodies against MAP. Therefore, understanding the structure of the specific 
markers and incorporating them in development of better diagnostic test could be achieved in 
future.    Further, it would be interesting to perform further studies on cellular immune responses 
against species-specific antigens in the ethanol extract. Indeed, a recent study showed that 
ethanol extract of MAP induced extensive inflammatory reactions in mouse model. 
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